HomeMy WebLinkAboutC2015-532 - 6/16/2015 - Approved EXPRESS SCRIPTS, INC.
PHARMACY BENEFIT MANAGEMENT AGREEMENT
THIS PHARMACY BENEFIT MANAGEMENT AGREEMENT ("Agreement") will be effective as of the
date set forth in Section 6.1 and is entered into by and between EXPRESS SCRIPTS, INC., a Delaware
corporation ("ESI"), and CITY OF CORPUS CHRISTI, organized under the laws of the state of Texas
("Sponsor").
RECITALS
A. ESI, either directly or through its subsidiaries, engages in pharmacy benefit management
services, including, among other things, pharmacy network contracting; pharmacy claims processing; mail and
specialty drug pharmacy; cost containment, clinical, safety, adherence, and other like programs; and formulary
administration ("PBM Services").
B. Sponsor provides or arranges for the provision of health benefits, including a prescription drug
benefit.
C. ESI and Sponsor desire that ESI be the exclusive provider of PBM Services for Sponsor's Plan
(as defined below) under the terms and conditions set forth herein.
THEREFORE, in consideration of the mutual promises contained herein, the parties hereto agree as
follows:
TERMS OF AGREEMENT
ARTICLE I -DEFINITIONS
"Ancillary Supplies, Equipment, and Services" or "ASES" means ancillary supplies, equipment, and
services provided or coordinated by ESI Specialty Pharmacy in connection with ESI Specialty Pharmacy's
dispensing of Specialty Products. ASES may include all or some of the following: telephonic and/or in-person
training, nursing/clinical services, in-home infusion and related support, patient monitoring, medication pumps,
tubing, syringes, gauze pads, sharps containers, lancets, test strips, other supplies, and durable medical
equipment. The aforementioned list is illustrative only (not exhaustive) and may include other supplies,
equipment, and services based on the patient's needs, prescriber instructions, payer requirements, and/or the
Specialty Product manufacturer's requirements.
"Average Wholesale Price" or "AWP" means the average wholesale price of a prescription drug as
identified by drug pricing services such as Medi-Span or other source recognized in the retail prescription drug
industry selected by ESI (the "Pricing Source"). The applicable AWP shall be the 11-digit NDC for the product
on the date dispensed, and for prescriptions filled in (a) Participating Pharmacies and ESI Specialty Pharmacy
will be the AWP for the package size from which the prescription drug was dispensed, and (b) in the Mail
Service Pharmacy the AWP for the smaller of: (i) the NDC code for the package size from which the prescription
drug was dispensed, or (ii) package sizes of 100 units or 16 ounce quantities, or the next larger quantity if such
specified quantities are not available. If the Pricing Source discontinues the reporting of AWP or Multi-Source
Indicator code identifiers or materially changes the manner in which AWP is calculated or its Multi-Source
Indicator code identifiers are reported, then ESI reserves the right to make an equitable adjustment as
necessary to maintain the parties' relative economics and the pricing intent of this Agreement.
"Brand/Generic Algorithm" or "BGA" means ESI's standard and proprietary brand/generic algorithm, a
copy of which may be made available for review by Sponsor or its Auditor upon request. The purposes of the
algorithm are to utilize a comprehensive and logical algorithm to determine the brand or generic status of
products in the ESI master drug file using a combination of industry standard attributes, to stabilize products
"flipping" between brand and generic status as may be the case when a single indicator is used from industry
pricing sources, and to reduce Sponsor, Member and provider confusion due to fluctuations in brand/generic
status. Sponsor or its Auditor may audit ESI's application of its BGA to confirm that ESI is making brand and
generic drug determinations consistent with such algorithm.
2015-532
6/16/15
Ord. 030531 221479.v4
Express Scripts Inc. INDEXED
"Brand Drug" means a prescription drug identified as such in ESI's master drug file using indicators from
First Databank (or other source nationally recognized in the prescription drug industry) on the basis of a
standard Brand/Generic Algorithm, a copy of which may be made available for review by Sponsor or its Auditor
upon request. Notwithstanding the foregoing, certain prescription drug medications that are licensed and then
currently marketed as brand name drugs, where there exists at least one (1) competing prescription medication
that is a generic equivalent and interchangeable with the marketed brand name drug, may process as "Generic
Drugs"for Prescription Drug Claim adjudication and Member Copayment purposes.
"Copayment" means that portion of the charge for each Covered Drug dispensed to the Member that is
the responsibility of the Member (e.g., copayment, coinsurance and/or deductible) as indicated on the Set-Up
Forms.
"Covered Drug(s)" means those prescription drugs, supplies, Specialty Products and other items that
are covered under the Plan, each as indicated on the Set-Up Forms.
"Eligibility Files" means the list submitted by Sponsor to ESI in reasonably acceptable electronic format
indicating persons eligible for drug benefit coverage services under the Plan.
"ESI National Plus Network" means ESI's broadest Participating Pharmacy network.
"ESI Specialty Pharmacy" means CuraScript, Inc., Accredo Health Group, Inc., Express Scripts
Specialty Distribution Services, Inc., or another pharmacy or home health agency wholly-owned or operated by
ESI or one or more of its affiliates that primarily dispenses Specialty Products or provides services related
thereto; provided, however, that when the Mail Service Pharmacy dispenses a Specialty Product, it shall be
considered an ESI Specialty Pharmacy hereunder.
"Formulary" means the list of FDA-approved prescription drugs and supplies developed by ESI's
Pharmacy and Therapeutics Committee and/or customized by Sponsor, and which is selected and/or adopted
by Sponsor. The drugs and supplies included on the Formulary will be modified by ESI from time to time as a
result of factors, including, but not limited to, medical appropriateness, manufacturer Rebate arrangements, and
patent expirations. Additions and/or deletions to the Formulary are hereby adopted by Sponsor, subject to
Sponsor's discretion to elect not to implement any such addition or deletion through the Set-Up Form process,
which such election shall be considered a Sponsor change to the Formulary.
"Generic Drug" means a prescription drug, whether identified by its chemical, proprietary, or non-
proprietary name, that is therapeutically equivalent and interchangeable with drugs having an identical amount
of the same active ingredient(s) and approved by the FDA, and which is identified as such in ESI's master drug
file using indicators from First Databank (or other source nationally recognized in the prescription drug industry)
on the basis of a standard Brand/Generic Algorithm, a copy of which may be made available for review by
Sponsor or its Auditor upon request.
"Ingredient Cost Charge" means the ingredient cost portion of the amount charged by ESI to Sponsor
for each Prescription Drug Claim, subject to the"lesser of" logic set forth on Exhibit A, as applicable.
"MAC List" means a list of off-patent prescription drugs or supplies subject to maximum reimbursement
payment schedules developed or selected by ESI.
"Mail Service Pharmacy" means a pharmacy wholly-owned or operated by ESI or one or more of its
affiliates, other than an ESI Specialty Pharmacy, where prescriptions are filled and delivered to Members via
mail delivery service.
"Manufacturer Administrative Fees" means those administrative fees paid by manufacturers to ESI in
connection with ESI's invoicing, allocating and collecting the Rebates under the Rebate program.
"Maximum Reimbursement Amount" or "MRA" means the maximum unit ingredient cost payable by
Sponsor for a drug on the MAC List based on maximum reimbursement payment schedule(s) developed or
selected by ESI. The application of MRA pricing may be subject to certain "dispensed as written" (DAW)
protocols and Sponsor defined plan design and coverage policies.
2
221479.v4
"Member" means each person who Sponsor determines is eligible to receive prescription drug benefits
as indicated in the Eligibility Files.
"Member Submitted Claim" means a paper claim submitted by a Member for Covered Drugs dispensed
by a pharmacy for which the Member paid cash.
"Participating Pharmacy" means any licensed retail pharmacy with which ESI or one or more of its
affiliates has executed an agreement to provide Covered Drugs to Members, but shall not include any mail order
or specialty pharmacy affiliated with any such Participating Pharmacy. Participating Pharmacies are
independent contractors of ESI.
"Plan" means any self-funded prescription drug benefit plan(s) administered by Sponsor or a subsidiary
or affiliate of Sponsor(including any retiree or Medicare employer group waiver plans).
"Prescription Drug Claim" means a Member Submitted Claim, Subrogation Claim or claim for payment
submitted to ESI by a Participating Pharmacy, Mail Service Pharmacy, or ESI Specialty Pharmacy as a result of
dispensing Covered Drugs to a Member.
"Rebates" mean retrospective formulary rebates that are paid to ESI pursuant to the terms of a
formulary rebate contract negotiated independently by ESI and directly attributable to the utilization of certain
Covered Drugs by Members. For sake of clarity, Rebates do not include, for example, Manufacturer
Administrative Fees; product discounts or fees related to the procurement of prescription drug inventories by
ESI Specialty Pharmacy or the Mail Service Pharmacy; fees received by ESI from pharmaceutical
manufacturers for care management or other services provided in connection with the dispensing of products; or
other fee-for-service arrangements whereby pharmaceutical manufacturers generally report the fees paid to ESI
or its wholly-owned subsidiaries for services rendered as "bona fide service fees" pursuant to federal laws and
regulations (collectively, "Other Pharma Revenue"). Such laws and regulations, as well as ESI's contracts with
pharmaceutical manufacturers, generally prohibit ESI from sharing any such "bona fide service fees" earned by
ESI, whether wholly or in part, with any ESI client.
"Set-Up Forms" means any standard ESI document or form, which when completed and signed by
Sponsor (electronic communications from Sponsor indicating Sponsor's approval of a Set-Up Form shall satisfy
the foregoing), will describe the essential benefit elements and coverage rules adopted by Sponsor for its Plan.
"Specialty Product List" means the standard list of Specialty Products and their reimbursement rates
applicable to Sponsor and maintained and updated by ESI from time to time. The Specialty Product List is
available to Sponsor upon request.
"Specialty Products" means those injectable and non-injectable drugs on the Specialty Product List.
Specialty Products, which may be administered by any route of administration, are typically used to treat chronic
or complex conditions, and typically have one or more of several key characteristics, including frequent dosing
adjustments and intensive clinical monitoring to decrease the potential for drug toxicity and increase the
probability for beneficial treatment outcomes; intensive patient training and compliance assistance to facilitate
therapeutic goals; limited or exclusive product availability and distribution (if a drug is only available through
limited specialty pharmacy distribution it is always considered a Specialty Product); specialized product handling
and/or administration requirements.
"Subrogation Claim" means subrogation claims submitted by any state or a person or entity acting on
behalf of a state under Medicaid or similar United States or state government health care programs, for which
Sponsor is deemed to be the primary payor by operation of applicable federal or state laws.
"UM Company" means MCMC, LLC or other independent third party utilization management company
contracted by ESI, subject to and as further described in Sections 2.3 (d) and (e).
"Usual and Customary Price" or "U&C" means the retail price charged by a Participating Pharmacy for
the particular drug in a cash transaction on the date the drug is dispensed as reported to ESI by the
Participating Pharmacy.
"Vaccine Claim" means a claim for a Covered Drug which is a vaccine.
3
221479.v4
"Vendor Transaction Fee" means the data interchange fee that ESI is charged by its third party vendor
to convert Vaccine Claims submitted electronically by physicians to NCPDP 5.1 format in order for ESI to
process the claim.
ARTICLE II - PBM SERVICES
2.1 Eligibility/Set Up. Sponsor will submit completed Set-Up Forms and Eligibility Files (initial and updated)
on a mutually determined basis, which ESI will accurately implement. Changes to the Set-Up Forms must be
documented on ESI's standard amendment forms. Eligibility performed manually by ESI for Sponsor, or
material changes to the Eligibility File processes requested by Sponsor during the term may be subject to
additional fees set forth on Exhibit A. Sponsor will be responsible for all Prescription Drug Claims during the
period of the Member's eligibility as indicated on the Eligibility File including for retroactively termed Members,
except in the event of ESI's negligence.
2.2 Pharmacy Network.
(a) Participating Pharmacies. ESI will maintain a network(s) of Participating Pharmacies as
identified in Exhibit A, and will make available an updated list of Participating Pharmacies on-line. ESI maintains
multiple networks and subnetworks, and periodically consolidates networks or migrates clients to other networks
and subnetworks. If, due to an access concern, Sponsor requests that ESI attempt to add a particular retail
pharmacy to the network of Participating Pharmacies serving Sponsor and its Members hereunder, ESI will
make commercially reasonable efforts to add any such pharmacy to the Participating Pharmacy network for
Sponsor, provided that such pharmacy meets ESI's network participation requirements and agrees to ESI's
standard terms and conditions. If any such pharmacy meets ESI's network participation requirements and
agrees to ESI's standard terms and conditions except for ESI's standard network rates (i.e., the particular
pharmacy will only agree to higher than standard reimbursement rates), and Sponsor nevertheless requests that
ESI add such pharmacy, the rate charged to Sponsor for Prescription Drug Claims processed through such
pharmacy (assuming ESI agrees to contract with such pharmacy) will be the net ingredient cost plus the
dispensing fee paid by ESI to such Participating Pharmacy (plus applicable sales or excise tax or other
governmental surcharge, if any). All such Prescription Drug Claims will be excluded from the pricing guarantees
set forth in Exhibit A.
(i) ESI will require each Participating Pharmacy to meet ESI's network participation
requirements, including but not limited to licensure, insurance and provider agreement requirements.
ESI also provides a standard suite of pharmacy audit services to determine Participating Pharmacies'
compliance with their provider agreement billing requirements. ESI will attempt recovery of identified
overpayments through offset, demand or other reasonable means; provided that ESI will not be required
to institute litigation. Recovered overpayments are credited to Sponsor. Copies of participation
requirements and auditing processes are available upon request.
(ii) ESI does not direct or exercise any control over the Participating Pharmacies or the
professional judgment exercised by any pharmacist in dispensing prescriptions or otherwise providing
pharmaceutical related services at a Participating Pharmacy. ESI shall have no liability to Sponsor, any
Member or any other person or entity for any act or omission of any Participating Pharmacy or it agents
or employees.
(b) Mail Service Pharmacy. Members may have prescriptions filled through the Mail Service
Pharmacy. Subject to applicable law, ESI may communicate with Members regarding benefit design, cost
savings, availability and use of the Mail Service Pharmacy, as well as provide supporting services. ESI may
suspend Mail Service Pharmacy services to a Member who is in default of any Copayment amount due ESI.
Sponsor will be responsible for any unpaid Member Copayment amounts if payment has not been received from
the Member within one hundred twenty (120) days following dispensing. Sponsor will be billed following the one
hundred twenty (120) day collection period, with payment due in accordance with the payment terms set forth in
Section 3.2 of this Agreement.
(c) Specialty Products and ASES. Members may have prescriptions filled through ESI Specialty
Pharmacy. Subject to applicable law, ESI and ESI Specialty Pharmacy may communicate with Members and
4
221479.v4
physicians to advise Members filling Specialty Products at Participating Pharmacies of the availability of filling
prescriptions through ESI Specialty Pharmacy. Specialty Products will be excluded from any price guarantees
set forth in the Agreement. In no event will the Mail Service Pharmacy or Participating Pharmacy pricing
specified in the Agreement apply to Specialty Products.
(i) ESI will notify Sponsor no more frequently than monthly of new Specialty Products that
are introduced to the market on or after the Effective Date of this Agreement with their applicable
reimbursement rates ("Notice"). The parties agree as follows:
(A) If Sponsor has expressly excluded a specific therapy class or product on a
Set-Up Form, Specialty Products in such excluded classes will automatically be deemed
excluded from coverage and will reject as "NDC Not Covered" through Participating
Pharmacies, Mail Service Pharmacy and ESI Specialty Pharmacy; otherwise, subject to (B)
below, all other Specialty Products will be implemented as Covered Drugs at the rate
specified in the applicable Specialty Drug list or Notice. If Sponsor desires to cover otherwise
excluded Specialty Products, Sponsor must notify ESI in writing that it desires to cover the
Specialty Product before ESI will adjudicate as a Covered Drug, and if ESI receives such
confirmation of coverage from Sponsor such Specialty Product will be loaded thereafter as a
Covered Drug at the applicable reimbursement rate set forth in the Notice.
(B) Sponsor must notify ESI in writing if it wants to exclude the Specialty Product
from coverage. The exclusion will be implemented within seven (7) business days after the
date of ESI's receipt of such notification. There will not be any retroactive denials for
Prescription Drug Claims processed prior to ESI's receipt of the rejection notice and
implementation of the exclusion as provided above and Sponsor will be responsible for the
payment of such Prescription Drug Claims processed prior to the rejection of coverage.
(ii) For Specialty Products filled through ESI Specialty Pharmacy only, Members may
receive the following services from ESI Specialty Pharmacy, depending on the particular therapy class
or disease state: ASES; patient intake services; pharmacy dispensing services and/or social services
(patient advocacy, hardship reimbursement support, and indigent and patient assistance programs).
(iii) Subject to Sponsor's prior authorization requirements, if applicable, at the rates set forth
in Exhibit A, ESI will provide or coordinate ASES for Members through ESI Specialty Pharmacy or
through other specialty pharmacies or other independent third party providers of ASES when ASES is
required. If ESI or ESI Specialty Pharmacy engages a third party provider of ASES, ESI or ESI
Specialty Pharmacy shall contractually obligate such third party provider of ASES to comply with all
applicable laws, including, without limitation, all applicable laws relating to professional licensure. ESI
does not direct or exercise any control over any third party provider of ASES in administering Specialty
Products or otherwise providing ASES.
(iv) Ancillary supplies, equipment, and services provided or coordinated in connection with
the dispensing of Specialty Products at Participating Pharmacies (for example, limited distribution
products not then available through ESI Specialty Pharmacy or overrides) will be billed to Sponsor at
the cost charged to ESI for such ancillary supplies, equipment, and services provided or coordinated,
unless such ancillary supplies, equipment, and services provided or coordinated are included in the
ingredient cost of the Specialty Product.
2.3 Claims Processing.
(a) Claims Processing.
(i) ESI will perform claims processing services for Covered Drugs dispensed by
Participating Pharmacies, Mail Service and ESI Specialty Pharmacy.
(ii) In connection with each prescription submitted for processing on-line by a Participating
Pharmacy, ESI will perform standard drug utilization review ("DUR") in order to assist the dispensing
pharmacist and prescribing physician in identifying potential drug interactions, incorrect prescriptions or
dosages, and certain other circumstances that may be indicative of inappropriate prescription drug
5
221479.v4
usage. ESI's DUR processes are not intended to substitute for the professional judgment of the
prescriber, the dispensing pharmacist or any other health care professional providing services to the
Member.
(iii) If elected by Sponsor, ESI will process Member Submitted Claims in accordance with
the rules in the Set-Up Forms and ESI's standard procedures.
(iv) If authorized by Sponsor on the Set-Up Forms, ESI will process Subrogation Claims in
accordance with applicable federal and state laws, in which case Sponsor will pay such Subrogation
Claims in accordance with Article III and Exhibit A. If Sponsor does not authorize ESI to process
Subrogation Claims, ESI will reject the claim and refer claimants to Sponsor regarding such claims, in
accordance with applicable federal and state laws. ESI is not legally responsible to pay Subrogation
Claims to the extent Sponsor is not timely paying ESI with respect to such Subrogation Claims.
(v) Sponsor or its third party designee (as applicable)will have the final responsibility for all
decisions with respect to coverage of a Prescription Drug Claim and the benefits allowable under the
Plan, including determining whether any rejected or disputed claim will be allowed.
(b) Prior Authorization. For the fees set forth in the Clinical Addendum described in Exhibit A-2 (if
applicable), ESI will provide prior authorization ("PA") services as specified and directed by Sponsor for drugs
designated on the Set-Up Form. Prior authorized drugs must meet Sponsor-approved guidelines ("Guidelines")
before they are deemed to be Covered Drugs. Unless Sponsor otherwise directs, Sponsor hereby authorizes
coverage for an otherwise excluded use in the event of co-morbidities, complications and other factors not
otherwise expressly set forth in the Guidelines. In determining whether to authorize coverage of such drug
under the PA Program, ESI will apply only the Guidelines and may rely entirely upon information about the
Member and the diagnosis of the Member's condition provided to it from the prescriber. ESI will not undertake
to determine medical necessity, make diagnoses or substitute ESI's judgment for the professional judgment and
responsibility of the prescriber.
(c) Claims for Benefits. ESI will process initial "claims for benefits" for Member Submitted Claims
and PA requests consistent with the ERISA claims rules set forth in 29 CFR Part 2560 (or applicable state law if
a non-ERISA plan) ("Claims Rules"). Sponsor may elect to have ESI perform appeals services in connection
with denied "claims for benefits" for the fees set forth in Exhibit A, or facilitate such services through Sponsor or
a third party of Sponsor's choice. If Sponsor elects to conduct its own appeals or facilitate through a third party
of Sponsor's choice, ESI will route Member appeals to Sponsor or other Sponsor designated entity. If Sponsor
elects to have ESI perform appeals services, Sponsor agrees that ESI may perform such services through the
UM Company. Through its contract with ESI, the UM Company has agreed to be, and will serve as, the named
fiduciary for its performance of such appeals. ESI also agrees to accept fiduciary status solely with respect to its
performance of any appeal.
(d) UM Company. In the event ESI performs appeals services, or facilitates the performance of
appeals services through the UM Company, ESI or the UM Company, as applicable, will be responsible for
conducting the appeal on behalf of Sponsor in accordance with the Claims Rules. ESI represents to Sponsor
that UM Company has contractually agreed that: (A) UM Company will conduct appeals in accordance with the
Claims Rules and Sponsor's plan, (B) Sponsor is a third party beneficiary of UM Company's agreement with ESI
(a copy of which is available upon request) and the remedies set forth therein, and (C) UM Company will
indemnify Sponsor for third party claims caused by the UM Company's negligence or willful misconduct in
providing the appeal services.
(e) External Review Services.
ESI will not conduct any external review services (as defined in the Patient Protection and Affordable
Care Act of 2010 and its implementing regulations ("PPACA")); provided, however, Sponsor may elect to have
UM Company facilitate the provision of external review services through UM company contracted IROs (as such
term is defined in PPACA), for the fees set forth on Exhibit A below (if applicable). Sponsor must execute a
standard ESI "External Appeals Services" Set-Up Form, which may be requested through ESI Account
Management, in order to receive such services from UM Company.
6
221479.v4
In the event that Sponsor elects to utilize UM Company to facilitate the provision of external review
services through UM Company contracted IROs, UM Company will be responsible for facilitating all such
appeals (and the IROs will be responsible for providing all such appeals) in accordance with PPACA and all
other applicable federal and state laws, and Sponsor hereby acknowledges and agrees that:
(i) UM Company (with respect to facilitating the external reviews) and the IROs (with
respect to performing the external reviews), and not ESI, will be providing external review services; UM
Company is an independent contractor of ESI; the IROs are independent contractors of UM Company
and not ESI; and ESI does not in any way control or direct either UM Company or the IROs with respect
to facilitation or performance of external review services provided by each respectively.
(ii) ESI represents to Sponsor that UM Company has contractually agreed that: (A) UM
Company will facilitate all external review services in accordance with PPACA and all other applicable
federal and state laws; (B) UM Company will contractually require its contracted IROs to perform all
external reviews in accordance with PPACA and all other applicable federal and state laws; (C) to the
extent not prohibited by law, UM Company will indemnify, defend and hold Sponsor harmless from and
against any and all losses, damages, injuries, causes of action, claims, demands and expenses
(including reasonable attorney's fees, costs and expenses), arising out of, resulting from, or related to
any act, omission or default by the IROs in their performance of the external reviews; and (D) Sponsor
has third party beneficiary rights to enforce the preceding indemnification and hold harmless provision.
(f) Call Center. ESI will provide 24-hours a day, 7-days a week toll-free telephone, IVR and
Internet support to assist Sponsor, Sponsor's agents and Members with Member eligibility and benefits
verification, location of Participating Pharmacies or other related Member concerns.
2.4 Formulary Support and Rebate Management.
(a) Formulary Adherence and Clinical Programs. ESI may provide clinical, safety, adherence, and
other like programs as appropriate. The Clinical Addendum described in Exhibit A-2 sets forth certain available
adherence, clinical, safety and/or trend programs that require additional fees hereunder. ESI will not implement
any program for which Sponsor may incur an additional fee without Sponsor's prior written approval and election
of such program.
(b) Rebate Program. Subject to the remaining terms of this Agreement, ESI will pay to Sponsor the
amounts set forth on Exhibit A.
2.5 Program Operations.
(a) Reporting. ESI will make available to Sponsor ESI's on-line standard management information
reporting applications. Upon Sponsor's request, ESI may develop special reporting packages or perform
custom programming at ESI's standard hourly rate for such services, as set forth in Exhibit A.
(b) Claims Data.
(i) Claims Data Retention. ESI will retain Sponsor's claims data for a total of ten (10)
years from the date the prescription is filled. Thereafter ESI will dispose of such data in accordance with
its standard policies and practices and applicable state and federal law. Disposition of PHI shall be in
accordance with the Business Associate Agreement.
(ii) Claims Data to Vendors. Upon Sponsor's written request and at no additional charge,
ESI will provide regular prescription claims data in ESI's standard format(s) to Sponsor's vendors
("Vendors") for disease management, flexible savings account and other "payment," "treatment" and
"healthcare operations" purposes (as defined under HIPAA). Requests for retrieval of data beyond thirty
(30) months are subject to the hourly custom programming charge set forth in Exhibit A.
(iii) De-Identified Claims Data. ESI or its affiliates may use and disclose both during and
after the term of this Agreement the anonymized claims data (de-identified in accordance with HIPAA)
including drug and related medical data collected by ESI or provided to ESI by Sponsor for research;
provider profiling; benchmarking, drug trend, and cost and other internal analyses and comparisons;
7
221479.v4
clinical, safety and/or trend programs; ASES; or other business purposes of ESI or its affiliates, in all
cases subject to applicable law.
(c) Sponsor Audits. Provided that this Agreement has been duly executed by Sponsor and
Sponsor is current in the payment of invoices under this Agreement, Sponsor may, upon no less than thirty (30)
days prior written request, audit ESI's provision of services hereunder, the scope of which shall be to verify
compliance with the financial terms of this Agreement, on an annual basis consistent with the Audit Protocol set
forth in Exhibit B. Sponsor may use an independent third party auditor("Auditor"), so long as such Auditor is not
engaged in providing services for Sponsor or otherwise that conflict with the scope or independent nature of the
audit (as determined by ESI acting reasonably and in good faith), and provided that Sponsor's Auditor executes
a mutually acceptable confidentiality agreement. Any request by Sponsor to permit an Auditor to perform an
audit will constitute Sponsor's direction and authorization to ESI to disclose PHI to the Auditor.
(d) Performance Standards. ESI will conform to the performance standards set forth on Exhibit E
hereto. The payments set forth in Exhibit E will be Sponsor's sole monetary remedy for any failure by ESI to
meet a performance standard in addition to any correction or reimbursement associated with payment or billing
errors.
2.6 Pharmacy Management Funds ("PMF").
(a) ESI will provide up to $4.00 per Member implemented as of the Effective Date, not to exceed
$21,000, to reimburse the actual, fair market value of: (i) expense items and services related to transitioning,
administering, and implementing the pharmacy benefit initially and throughout the term, such as, custom ID
Cards, IT programming, custom formulary letters, member communications, and benefit set-up quality
assurance; and/or (ii) mutually agreed upon expense items and services related to implementation of additional
clinical or other similar programs provided by ESI throughout the Term; in either case subject to submission of
adequate documentation to support reimbursement within 180 days of incurring the applicable expense. Both
Sponsor and ESI (upon agreement from Sponsor) may use the PMF to cover the fair market value of expenses
for projects requiring joint resources. All reimbursement under the PMF is subject to ESI's standard PMF
business practices for all clients.
(b) Sponsor represents and warrants that: (i) it will only request reimbursement under the PMF for
its actual expenses incurred in transitioning, administering, and implementing the pharmacy benefit managed by
ESI hereunder, and/or the additional clinical or other similar program provided by ESI throughout the Term; (ii)
that the applicable service, item or program was actually performed or provided; (iii) the amount of the
reimbursement is equal to or less than the reasonable fair market value of the actual expenses incurred by
Sponsor; (iv) it will notify and disclose the amount and the terms of any PMF reimbursements to Members and
other third parties to the extent required by applicable laws and regulations. In addition, if the Sponsor and the
Plan are subject to ERISA, Sponsor represents and warrants that it will only request reimbursement under the
PMF for items or services for which Sponsor, in the absence of the PMF, would be allowed reimbursement from
the Plan (i.e., not"settlor functions").
(c) Sponsor shall comply with all applicable federal and state requirements, including, but not
limited to, all applicable federal and state reporting requirements with respect to any expense, item or service
reimbursed under this Section 2.6. ESI reserves the right to periodically audit the books and records of Sponsor
on-site, during normal business hours and after giving reasonable advance notice, for the purposes of verifying
Sponsor's compliance with the PMF requirements set forth in this Agreement.
(d) ESI intends to amortize the PMF over the Initial Term of the Agreement on a straight-line basis.
In the event of a termination of this Agreement for any reason other than ESI's uncured material breach prior to
the expiration of the Initial Term, Sponsor will reimburse ESI an amount equal to any paid but unamortized
portion of the PMF. Reimbursement to ESI by Sponsor pursuant to this Section will not be in lieu of any other
rights or remedies ESI may have in connection with the termination of this Agreement, including monetary or
other damages. PMF reimbursements shall not be paid prior to the Effective Date of this Agreement and are not
payable until this Agreement is executed. Sponsor will have no right to interest on, or the time value of, any
PMF, and unused funds shall be retained by ESI.
8
221479.v4
ARTICLE III -FEES; BILLING AND PAYMENT
3.1 Fees. In consideration of the PBM Services provided by ESI, Sponsor will pay the applicable claims
reimbursement amounts ("Claims Reimbursements") and other administrative fees ("Administrative Fees")
pursuant to the terms set forth on Exhibit A ("Claims Reimbursements," "Administrative Fees" and any other
charge or fee that is the responsibility of Sponsor as may be described elsewhere in this Agreement are
hereinafter referred to collectively as "Fees"). ESI may use any excess achieved in any guarantee offered
pursuant to this Agreement to make up for, and offset, a shortfall in any other guarantee set forth in this
Agreement.
3.2 Billing and Payment.
(a) Billing. ESI will invoice Sponsor bi-weekly for all applicable Fees.
(b) Payment. Sponsor will pay ESI by wire, ACH transfer or pre-authorized debit within two (2)
business days from the date of Sponsor's receipt of each ESI invoice. Sponsor will be responsible for all costs
of collection, and agrees to reimburse ESI for such costs and expenses, including reasonable attorneys' fees.
All amounts not paid by the due date thereof will bear interest at the rate of 1.5% per month or, if lower, the
highest interest rate permitted by law. In addition to any rights under Section 6.2, ESI may apply Rebate
amounts otherwise owed to Sponsor against any unpaid Fees.
(c) Deposit. If, at any time: (i) Sponsor has two or more invoices past due and outstanding, or (ii)
ESI has reasonable grounds to believe Sponsor may be delinquent in payment of fees based on Sponsor's
financial data (e.g., persistent negative cash flow, bankruptcy or insolvency), ESI may require that the Sponsor
provide to ESI a deposit in an amount equal to the average of the last three (3) months of billing history as the
basis for determining the one (1) month deposit amount or, if three (3) months billing history is not available, the
most recent month of billing history as the basis. ESI will retain the deposit until the earlier of termination of this
Agreement (following any run-off period), or six (6) consecutive months of timely payments of all Fees following
submission of the deposit, and may apply the deposit to delinquent fees until return of the deposit.
ARTICLE IV—HIPAA; CONFIDENTIAL INFORMATION
4.1 HIPAA. The parties agree that as relates to use and disclosure of PHI, electronic transaction standards
and security of electronic PHI under the Health Insurance Portability and Accountability Act of 1996, as
amended, they are subject to the terms of the Business Associate Agreement set forth in Exhibit C.
Notwithstanding the foregoing, the parties acknowledge that in providing services to Members, ESI Specialty
Pharmacy and the Mail Service Pharmacy are acting as separate health care provider covered entities under
HIPAA and not as business associates to the Plan covered by the Business Associate Agreement. In providing
services, ESI Specialty Pharmacy and the Mail Services Pharmacy shall abide by all HIPAA requirements
applicable to covered entities and shall safeguard, use and disclose Member PHI accordingly.
4.2 Confidential Information.
(a) Each party agrees that the terms of this Agreement and information of the other party, including,
but not limited to the following, will constitute confidential and proprietary information ("Confidential
Information"): (i) with respect to ESI: ESI's reporting and other web-based applications, eligibility and
adjudication systems, system formats and databanks (collectively, "ESI's Systems"), clinical or formulary
management operations or programs, fraud, waste and abuse tools and programs, anonymized claims data (de-
identified in accordance with HIPAA); ESI Specialty Pharmacy and Mail Service Pharmacy data; information and
contracts relating to Rebates and Manufacturer Administrative Fees, prescription drug evaluation criteria, drug
pricing information, and Participating Pharmacy agreements; and (ii) with respect to Sponsor: Participating
Pharmacy Sponsor and Member identifiable health information and data, Eligibility Files, Set-Up Form
information, business operations and strategies. Neither party will use the other's Confidential Information, or
disclose it or this Agreement to any third party (other than Sponsor attorneys and accountants), at any time
during or after termination of this Agreement, except as specifically contemplated by this Agreement or upon
prior written consent, which will not unreasonably be withheld. Upon termination of this Agreement, each party
will cease using the other's Confidential Information, and all such information will be returned or destroyed upon
the owner's direction. Confidential Information does not include information which is or becomes generally
available to the public; was within the recipient's possession or knowledge prior to its being furnished to the
9
221479.v4
recipient pursuant to this Agreement, or is independently developed by the recipient under circumstances not
involving a breach of this Agreement.
(b) Sponsor will not, and will not permit any third party acting on Sponsor's behalf to, access,
attempt to access, test or audit ESI's Systems or any other system or network connected to ESI's Systems.
Without limiting the foregoing, Sponsor will not: access or attempt to access any portion or feature of ESI's
Systems, by circumventing ESI's Systems access control measures, either by hacking, password "mining" or
any other means; or probe, scan, audit or test the vulnerability of ESI's Systems, nor breach the security or
authentication measures of ESI's Systems.
ARTICLE V-COMPLIANCE WITH LAW; FIDUCIARY ACKNOWLEDGEMENTS; FINANCIAL DISCLOSURE
5.1 Compliance with Law; Change in Law. Each party shall be responsible for ensuring its compliance with
any laws and regulations applicable to its business, including maintaining any necessary licenses and permits.
Sponsor shall be responsible for any governmental or regulatory charges and taxes imposed upon or related to
the services provided hereunder. With respect to any Plan that is subject to the provisions of ERISA, the
Sponsor or the plan sponsor shall ensure that its activities in regard to such program are in compliance with
ERISA, and shall be responsible for disclosing to Members any and all information relating to the Plan and this
Agreement as required by law to be disclosed, including any information relating to Plan coverage and eligibility
requirements, commissions, rebates, discounts, or provider discounts referred to in Section 5.3 hereof. If there
is a new or change in federal or state laws or regulations or the interpretation thereof, or any government,
judicial or legal action that, among other things, materially burdens ESI, requires ESI to increase payments or
shorten payment times for Covered Drugs to Participating Pharmacies, or materially changes the scope of
services hereunder (a "Change in Law"), then there shall be an appropriate modification of the services,
reimbursement rates, Administrative Fees and/or Rebates hereunder. If the parties cannot agree on a
modification or adjusted fee or rates, then either party may terminate the Agreement on thirty (30) days prior
written notice to the other.
5.2 Fiduciary Acknowledgements. ESI offers pharmacy benefit management services, products and
programs ("PBM Products") for consideration by all clients, including Sponsor. The general parameters of the
PBM Products, and the systems that support these products, have been developed by ESI as part of ESI's
administration of its business as a PBM. The parties agree that they have negotiated the financial terms of this
Agreement in an arm's-length fashion. Sponsor acknowledges and agrees that, except for the limited purpose
set forth in Section 2.3(c), neither it nor the Plan intends for ESI to be a fiduciary (as defined under ERISA or
state law) of the Plan, and, except for the limited purpose as set forth in Section 2.3(c), neither will name ESI or
any of ESI's wholly-owned subsidiaries or affiliates as a "plan fiduciary." Sponsor further acknowledges and
agrees that neither ESI nor any of ESI's wholly-owned subsidiaries or affiliates: (a) have any discretionary
authority or control respecting management of the Plan's prescription benefit program, except as set forth in
Section 2.3(c), or(b) exercise any authority or control respecting management or disposition of the assets of the
Plan or Sponsor. Sponsor further acknowledges that all such discretionary authority and control with respect to
the management of the Plan and plan assets is retained by Sponsor or the Plan. Upon reasonable notice, ESI
will have the right to terminate PBM Services to any Plan (or, if applicable, Members) located in a state requiring
a pharmacy benefit manager to be a fiduciary to Sponsor, a Plan, or a Member in any capacity.
5.3 Disclosure of Certain Financial Matters. In addition to the Administrative Fees paid to ESI by Sponsor,
ESI and ESI's wholly-owned subsidiaries or affiliates derive revenue in one or more of the ways as further
described in the Financial Disclosure to ESI PBM Clients set forth in Exhibit D hereto ("Financial Disclosure"), as
updated by ESI from time to time. Unlike the Administrative Fees, the revenues described in the Financial
Disclosure are not direct or indirect compensation to ESI from Sponsor for services rendered to Sponsor or the
Plan under this Agreement. In negotiating any of the fees and revenues described in the Financial Disclosure or
in this Agreement, ESI and ESI's wholly-owned subsidiaries and affiliates act on their own behalf, and not for the
benefit of or as agents for Sponsor, Members or the Plan. ESI and ESI's wholly-owned subsidiaries and
affiliates retain all proprietary rights and beneficial interest in such fees and revenues described in the Financial
Disclosure and, accordingly, Sponsor acknowledges that neither it, any Member, nor the Plan, has a right to
receive, or possesses any beneficial interest in, any such fees or revenues; provided, that ESI will pay Sponsor
amounts equal to the amounts expressly set forth on Exhibit A.
10
221479.v4
ARTICLE VI-TERM AND TERMINATION; DEFAULT AND REMEDIES
6.1 Term.
(a) This Agreement will commence effective as of October 1, 2015 ("Effective Date"), and will
continue for a period of three (3) years ("Initial Term"), and may be terminated earlier or extended in accordance
with the terms of Section 6.2 below. Thereafter, this Agreement will automatically renew with the same terms
and conditions as set forth herein for successive one (1) year renewal terms, subject to the right of termination
as otherwise provided herein.
(b) Sponsor may terminate this Agreement with or without cause upon twenty (20) days prior
written notice to ESI.
6.2 Termination.
(a) Breach or Default. Either party may give the other written notice of a material, substantial and
continuing breach of this Agreement. If the breaching party has not cured said breach within thirty (30) days
from the date such notice was sent, this Agreement may be terminated at the option of the non-breaching party.
If the amount of time commercially reasonable for the breach to be cured is longer than thirty (30) days, this
Agreement may not be terminated by the non-breaching party pursuant to this provision until such commercially
reasonable period of time has elapsed; provided, however, that in no event will such period exceed sixty (60)
days.
(b) Non-Payment. Notwithstanding anything to the contrary herein, ESI (and its wholly-owned
subsidiaries) may terminate or suspend their performance hereunder and cease providing or authorizing
provision of Covered Drugs to Members upon forty-eight (48) hours written notice if Sponsor fails to pay ESI or
provide a deposit, if required, in accordance with the terms of this Agreement. ESI attempts collection through
written and verbal communications with Sponsor prior to sending the notice described herein.
(c) Obligations Upon Termination. Upon notice of termination of this Agreement, the parties will
mutually develop a run-off plan providing for: (i) Sponsor notification to Members of the timing of any transition
to a successor pharmacy benefit manager at least thirty (30) days prior to the effective date of such termination;
(ii) ESI provision of open Mail Service Pharmacy refill files and standard claims data and PA files for transition to
the successor pharmacy benefit manager in accordance with then existing industry protocol; and (iii) whether
Sponsor elects for ESI to process Participating Pharmacy or Member Submitted Claims for prescriptions filled
during the Term but filed with ESI after the effective date of termination ("Termination Date"). Sponsor will
continue to pay ESI in accordance with this Agreement for any Fees for PBM Services provided during the term
and any run-off period. ESI will continue filing for Rebates for claims incurred prior to the Termination Date and
will, subject to final reconciliation of any outstanding amounts owed by Sponsor to ESI, pay Sponsor Rebates for
such claims in accordance with the Rebate payment schedule set out herein. Notwithstanding anything in this
Agreement to the contrary, ESI shall not be obligated to provide post-transition services following the transition
to the successor pharmacy benefit manager and conclusion of the run-off period, including, but not limited to,
the provision of continued data reporting, reporting, consultation, or analysis.
6.3 Remedies.
(a) Remedies Not Exclusive. A party's right to terminate this Agreement under Article VI will not be
exclusive of any other remedies available to the terminating party under this Agreement or otherwise, at law or
in equity.
(b) Force Majeure. Neither party will lose any rights under this Agreement or be liable in any
manner for any delay to perform its obligations under this Agreement that are beyond a party's reasonable
control, including, without limitation, any delay or failure due to riots, earthquakes, storms, floods or other
extreme weather conditions, fires, acts of terrorism, epidemics, embargoes, war or other outbreak of hostilities,
government acts or regulations, the failure or inability of carriers, suppliers, or telecommunications providers to
provide services necessary to enable a party to perform its obligations hereunder, or any other reason where
failure to perform is beyond the party's reasonable control, and is not caused by the negligence, intentional
conduct or misconduct of the defaulting party; provided, however, that this clause may not be invoked to excuse
11
221479.v4
a party's payment obligations hereunder. ESI represents that it maintains and continually updates a business
continuity plan designed to mitigate any disruption to the services provided by ESI under this Agreement.
(c) Limitation of Liability. Except for the indemnification obligations set forth in Section 6.3(d), each
party's liability to the other hereunder will in no event exceed the actual proximate losses or damages caused by
breach of this Agreement. In no event will either party or any of their respective affiliates, directors, employees
or agents, be liable for any indirect, special, incidental, consequential, exemplary or punitive damages, or any
damages for lost profits relating to a relationship with a third party, however caused or arising, whether or not
they have been informed of the possibility of their occurrence.
(d) Indemnification.
(i) In addition to any indemnification obligations set forth in the Business Associate
Agreement, ESI will indemnify and hold Sponsor harmless from and against any loss, cost, damage,
expense or other liability, including, without limitation, reasonable costs and attorney fees ("Costs")
incurred in connection with any and all third party claims, suits, investigations or enforcement actions
("Claims")which may be asserted against, imposed upon or incurred by Sponsor and arising as a result
of (A) ESI's negligent acts or omissions or willful misconduct (including those of the Mail Service
Pharmacy and ESI Specialty Pharmacy), or(B) ESI's breach of this Agreement.
(ii) As a condition of indemnification, the party seeking indemnification will notify the
indemnifying party in writing promptly upon learning of any Claim for which indemnification may be
sought hereunder, and will tender the defense of such claim to the indemnifying party. No party will be
obligated to indemnify the other with respect to any claim settled without the written consent of the
other.
6.4 Survival. The parties' rights and obligations under the Sections 2.5, Articles III, IV and V; and Sections
6.2(c), 6.3, 6.4, 7.2, 7.3, 7.4 and 7.6 will survive the termination of this Agreement for any reason.
ARTICLE VII—MISCELLANEOUS
7.1 Liability Insurance. Each party will maintain such policies of general liability, professional liability and
other insurance of the types, including self-insurance, and in amounts customarily carried by their respective
businesses. Proof of such insurance will be available upon request. ESI agrees, at its sole expense, to maintain
during the term of this Agreement or any renewal hereof, commercial general liability insurance, pharmacists
professional liability insurance for the Mail Service and ESI Specialty Pharmacy pharmacies, and managed care
liability with limits, excess of a self-insured retention, in amounts of not less than $5,000,000 per occurrence and
in the aggregate. ESI does not maintain liability insurance on behalf of any Participating Pharmacy, but does
contractually require such pharmacies to maintain a minimum amount of commercial liability insurance or, when
deemed acceptable by ESI, to have in place a self-insurance program
7.2 Notice. Any notice or document required or permitted to be delivered pursuant to this Agreement must
be in writing and will be deemed to be effective upon mailing and must be either (a) deposited in the United
States Mail, postage prepaid, certified or registered mail, return receipt requested, or (b) sent by recognized
overnight delivery service, in either case properly addressed to the other party at the address set forth below, or
at such other address as such party will specify from time to time by written notice delivered in accordance
herewith:
Express Scripts, Inc.
Attn: President
One Express Way
St. Louis, Missouri 63121
With copy to Legal Department
Fax No. (800)417-8163
City of Corpus Christi
Attn: Steve Viera
1201 Leopard Street
12
221479.v4
Corpus Christi, Texas 78401
7.3 Independent Parties. No provision of this Agreement is intended to create or will be construed to create
any relationship between ESI and Sponsor other than that of independent entities contracting with each other
solely for the purpose of effecting the provisions of this Agreement. Neither party, nor any of their respective
representatives, will be construed to be the partner, agent, fiduciary, employee, or representative of the other
and neither party will have the right to make any representations concerning the duties, obligations or services
of the other except as consistent with the express terms of this Agreement or as otherwise authorized in writing
by the party about which such representation is asserted.
7.4 Assignment and Subcontracting. Sponsor may assign this Agreement upon first obtaining ESI's written
consent, which consent will not be unreasonably withheld following a standard credit review of the proposed
assignee. Sponsor acknowledges and agrees that ESI may perform certain services hereunder (e.g., mail
service pharmacy and specialty pharmacy services) through one or more ESI subsidiaries, affiliates, or
designees. ESI is responsible and liable for the performance of its subsidiaries and affiliates in the course of
their performance of any such service. To the extent that ESI subcontracts any PBM Service under this
Agreement to a third party, ESI is responsible and liable for the performance of any such third party. In addition,
ESI may contract with third party vendors to provide information technology support services and other ancillary
services, which services are not PBM Services hereunder, but rather are services that support ESI's conduct of
its business operations. This Agreement will be binding upon, and inure to the benefit of and be enforceable by,
the respective successors and permitted assigns of the parties hereto.
7.5 Integration; Amendments. This Agreement and any Exhibits hereto constitute the entire understanding
of the parties hereto and supersedes any prior oral or written communication between the parties with respect to
the subject matter hereof. If there is a separate Business Associate Agreement between the parties, such an
agreement will be incorporated herein for all applicable purposes. No modification, alteration, or waiver of any
term, covenant, or condition of this Agreement will be valid unless in writing and signed by the parties or the
agents of the parties who are authorized in writing, except as may be otherwise permitted pursuant to the terms
and conditions of this Agreement or any Exhibit hereto.
7.6 Choice of Law. This Agreement will be construed and governed in all respects according to the laws in
the State of Texas, without regard to the rules of conflict of laws thereof.
7.7 Waiver. The failure of either party to insist upon the strict observation or performance of this Agreement
or to exercise any right or remedy will not be construed as a waiver of any subsequent breach of this Agreement
or impair or waive any available right or remedy.
7.8 Trademarks. Each party acknowledges each other party's sole and exclusive ownership of its
respective trade names, commercial symbols, trademarks, and servicemarks, whether presently existing or later
established (collectively "Marks"). No party shall use the other party's Marks in advertising or promotional
materials or otherwise without the owner's prior written consent.
7.9 Taxes and Assessments. Any applicable sales, use, excise, or other similarly assessed and
administered tax, surcharge, or fee imposed on items dispensed, or services provided hereunder, or the fees or
revenues generated by the items dispensed or services provided hereunder, or any other amounts ESI or one or
more of its subsidiaries or affiliates may incur or be required to pay arising from or relating to ESI's or its
subsidiaries' or affiliates' performance of services as a pharmacy benefit manager, third-party administrator, or
otherwise in any jurisdiction, will be the sole responsibility of Sponsor or the Member. If ESI is legally obligated
to collect and remit, or to incur or pay, any such sales, use, excise, or other similarly assessed and administered
tax, surcharge, or fee in a particular jurisdiction, such amount will be reflected on the applicable invoice or
subsequently invoiced at such time as ESI becomes aware of such obligation or as such obligation becomes
due. ESI reserves the right to charge a reasonable administrative fee for collection and remittance services
provided on behalf of Sponsor.
7.10 Third Party Beneficiary Exclusion. This Agreement is not a third party beneficiary contract, nor will this
Agreement create any rights on behalf of Members as against ESI. Sponsor and ESI reserve the right to
amend, cancel or terminate this Agreement without notice to, or consent of, any Member.
13
221479.v4
7.11 Authority to Contract. Sponsor hereby represents and warrants that it has obtained due and proper
authority to enter into this Agreement through its governing body.
7.12 Open Records Requests. ESI acknowledges that Sponsor, as a government agency, may be subject to
applicable freedom of information or open records laws and must, upon request, disclose such materials as are
covered by and not exempted from such laws. Pursuant to Section 4.2 hereof, Sponsor acknowledges that
certain information contained herein or subject to this Agreement is proprietary and confidential to ESI and shall
be exempt from that Act to the fullest extent permitted by law. Sponsor agrees to give ESI notice and the
minimum statutory or regulatory period of time to oppose, request redactions or limitations on any disclosures
under a third party freedom of information or open records request pertaining to this Agreement or any proposal
related hereto. This provision shall survive termination of the Agreement.
7.13 Conflict of Interest. Consultant agrees to comply with Chapter 176 of the Texas Local Government
Code and file Form CIQ with the City Secretary's Office, if required.
7.14 Certificate of Interested Parties. Consultant agrees to comply with Texas Government Code section
2252.908 and complete Form 1295 Certificate of Interested Parties as part of this Agreement.
IN WITNESS WHEREOF, the undersigned have executed this Pharmacy Benefit Management
Agreement as of the day and year below set forth.
CITY OF CORPUS CHRISTI EXPRESS SCRIPTS, INC.
By: V/vutit) a .
Printed Name: Margie C. Rose Printed Name:
David L Brodsky
Title: City Manager Title: Vlo.President-Commercial Division
Federal ID Number: -7 !oZ e l —O 16
Q Date:
Date: U' I ' 1 '
ATTEST:
fit
Rebecca Huerta
City Secretary
l 7-211 Ovd 03D531
1
Date .._.....a...... ....._ U1UsfILtt
IY COUNCIL
APPROVED AS TO LEGAL FORM:
7 fX/11 1� 0 —I TIN
SEC ARv
Buck Brice (Date)
Assistant City Attorney
For City Attorney
14
221479.v4
EXHIBIT A
PHARMACY PROGRAM FEES
ESI shall be Sponsor's exclusive provider of PBM Services for Sponsor's Plans offering a prescription
benefit. The financial terms set forth in Exhibit A are conditioned on such exclusive arrangement and all other
specified conditions expressly incorporated in such exhibits, including, but not limited to the adoption by
Sponsor of the specified network, qualifying co-payment structures, Formulary, a minimum of 5,100 Members
implemented on the Effective Date of this Agreement, no Members in a 100% co-payment plan or a consumer
driven health plan (CDHP). In the event one or more of the following occurs (whether between the date of the
Cost Proposal and the Effective Date, or during the Term), ESI will have the right, upon notice, to make an
equitable adjustment to the rates, Administrative Fees and/or Rebates, solely as necessary to return ESI to its
contracted economic position as of the effective date of such event:
(a) There is a material change in: (i) the conditions or assumptions stated in this Agreement; or (ii)
the size, demographics or gender distribution of Sponsor's Membership compared to data provided by Sponsor;
and/or
(b) Sponsor changes its Formulary, benefit designs, implements OTC plans, clinical or trend
programs or otherwise takes an action that has the effect of lowering the amount of Rebates earned hereunder
or materially impacting any guarantee; and/or
(c) Sponsor elects to use on-site clinics or pharmacies to dispense prescription drugs to Members
which materially reduces Rebates and/or the number of Covered Drug claims submitted on-line; and/or
(d) More than 5% of claims are incurred in Massachusetts, Hawaii, Alaska, or Puerto Rico; and/or
(e) Rebate revenue is materially decreased because Brand Drugs move off-patent to generic status
or due to a Change in Law.
Exhibit A includes the following:
Exhibit A-1
Pharmacy Reimbursement Rates
Exhibit A-2
Administrative and Clinical Program Fees
Exhibit A-3
Rebates— Non-Specialty Products
Exhibit A-4
Rebates—Specialty Products
15
221479.v4
Exhibit A-1
Pharmacy Reimbursement Rates
Annual Average Ingredient Cost Discount Guarantees(Does Not Apply to Specialty Products)
Brand Generic
Participating PharmacyYear 1:AWP-76.50%
Year 1:AWP-16.75°/°
ESI National Plus Network Year 2:AWP-77.00%
Year 2&3:AWP-17.00%
Year 3:AWP-77.50%
Mail Service Pharmacy Year 1:AWP-76.50%
(1-45 Days'Supply) Year 1:AWP-16.75/° Year 2:AWP-77.00%
Year 2&3:AWP-17.00%
Year 3:AWP-77.50%
Mail Service Pharmacy Year 1:AWP-79.50%
(46-90 Days'Supply) Year 1:AWP-24.25% Year 2:AWP-80.00%
Year 2&3:AWP-24.50%
Year 3:AWP-80.50%
Subject to annual reconciliation of the above average guarantees, Sponsor will pay to ESI on a per
Prescription Drug Claim basis amounts determined pursuant to the following, net of applicable
Copayments:
Participating Pharmacy-Brand: The lesser of the Ingredient Cost Charge or U&C plus the applicable dispensing
fee
Participating Pharmacy- Generic: The lesser of the Ingredient Cost Charge, MRA, or U&C plus the applicable
dispensing fee
Mail Service Pharmacy-Brand: The Ingredient Cost Charge plus the applicable dispensing fee
Mail Service Pharmacy - Generic: The lesser of the Ingredient Cost Charge or MRA plus the applicable
dispensing fee
A Member's Copayment charged for a Covered Drug will be the lesser of the applicable Copayment,
Ingredient Cost Charge, or U&C.
Applicable dispensing fees as well as additional per/Rx Administrative Fees, if any, are set forth in the
table in Section II. below. Sales or excise tax or other governmental surcharge, if any, will be the
responsibility of Sponsor.
All compound Prescription Drug Claims shall be excluded from the average annual ingredient cost
discount guarantees set forth in the table above and will be paid by Sponsor at the lesser of U&C or
combined AWP plus applicable service fee for Participating Pharmacy.
Application of the average annual ingredient cost discount guarantees set forth in the table above shall
be subject to the following criteria and reconciliation provisions:
A. Guarantee Methodology. Notwithstanding anything in this Agreement to the contrary, the
Generic average annual ingredient cost discount guarantees set forth above will include only
those Prescription Drug Claims that processed to Sponsor for payment where the underlying
prescription drug product was identified by Medi-Span as having a Multi-Source Indicator code
identifier of"Y" on the date dispensed (or was identified by Medi-Span as having a Multi-Source
Indicator identifier of an "M," "N," or "0" on the date dispensed, but was substituted and
dispensed by the Mail Service Pharmacy as its "house generic"), unless such Prescription Drug
Claim is otherwise excluded above. The Brand average annual ingredient discount guarantees
set forth above will include only those Prescription Drug Claims that processed to Sponsor for
payment where the underlying prescription drug product was identified by Medi-Span as having
a Multi-Source Indicator code identifier of "M", "N", or "0" on the date dispensed (except in
16
221479.v4
cases where the underlying prescription drug product was substituted and dispensed by the
Mail Service Pharmacy as its "house generic"), unless such Prescription Drug Claim is
otherwise excluded above.
B. Guarantee Exclusions. Prescription Drug Claims for OTCs, compounds, Member Submitted
Claims, Subrogation Claims, vaccines, Specialty Products, biosimilar products, long term care
pharmacy claims, home infusion, I/T/U, IHS, and products filled through in-house or 340b
pharmacies (if applicable) shall be excluded from the reconciliation of all guarantees.
C. Guarantee Calculation. Separately for each pricing component in the table above, the
following calculation will be performed on an aggregated basis for all Prescription Drug Claims
processed during the applicable contract year in order to reconcile against the average annual
ingredient cost discount guarantees set forth in the table above:
1 -(A/B)
A= For Participating Pharmacy- Brand Prescription Drug Claims, the lesser of the Ingredient Cost Charge or
U&C,and prior to application of Copayments
For Participating Pharmacy- Generic Prescription Drug Claims, the lesser of the Ingredient Cost Charge,
MRA,or U&C,and prior to application of Copayments
For Mail Service Pharmacy - Brand Prescription Drug Claims, the Ingredient Cost Charge, and prior to
application of Copayments
For Mail Service Pharmacy-Generic Prescription Drug Claims, the lesser of the Ingredient Cost Charge or
MRA,and prior to application of Copayments
B = The actual AWP for the Covered Prescription
D . Guarantee Reconciliation. Guarantees will be measured and reconciled on an annual basis
within ninety (90) days of the end of each contract year. The above guarantees are annual
guarantees - if this Agreement is terminated prior to the completion of the then current contract
year (hereinafter, a "Partial Contract Year"), then the above guarantees will not apply for such
Partial Contract Year. To the extent Sponsor changes its benefit design or Formulary during the
term of the Agreement, the guarantee will be equitably adjusted if there is a material impact on
the discount achieved. Subject to the remaining terms of this Agreement, ESI will pay the
difference attributable to any shortfall between the actual result and the guaranteed result;
provided however, that ESI may use an excess achieved in one or more of the above
guarantees to make up for, and offset, a shortfall in another guarantee. ESI may also use any
excess achieved in any other guarantee offered pursuant to this Agreement to make up for, and
offset, a shortfall in any of the above guarantees or any other guarantee(s) set forth in this
Agreement, excluding Rebates.
17
221479.v4
II. Per Prescription Drug Claim Dispensing Fee Guarantees and Administrative Fees (Does Not
Apply to Specialty Products).
ESI National Plus Network Brand Generic
Participating Pharmacy $0.90 $0.90
Dispensing Fee1Rx
Participating Pharmacy $0.00 $0.00
Administrative FeelRx
Mail Service Pharmacy
Dispensing Fee1Rx* $0.90 $0.90
(1-45 Days'Supply)
Mail Service Pharmacy
Dispensing Fee1Rx* $0.00 $0.00
(46-90 Days'Supply)
Mail Service Pharmacy $0.00 $0.00
Administrative Fee1Rx
*Dispensing Fee Guarantee are inclusive of shipping and handling. If carrier rates(i.e.,U.S.mail and/or applicable commercial
courier services)increase during the term of this Agreement,the Dispensing Fee Guarantee will be increased to reflect such
increase(s).
Guarantee Exclusions. Prescription Drug Claims for OTCs, compounds, Member Submitted Claims,
Subrogation Claims, vaccines, Specialty Products, biosimilar products, long term care pharmacy claims, home
infusion, IR/U, IHS, and products filled through in-house or 340b pharmacies (if applicable) shall be excluded
from the reconciliation of all guarantees.
III. Specialty Products
(a) Exclusive Care. ESI Specialty Pharmacy is the exclusive provider of Specialty Products for the
reimbursement rates shown on the Exclusive ESI Specialty Pharmacy Specialty Product List. Any Specialty
Product dispensed at a Participating Pharmacy (for example, limited distribution products not then available
through ESI Specialty Pharmacy or overrides) will be reimbursed at the standard Participating Pharmacy
Specialty Product rates shown below. Upon ESI Specialty Pharmacy acquisition of limited distribution products,
Members will obtain prescriptions through ESI Specialty Pharmacy.
Ingredient Cost Dispensing Fee
Exclusive ESI Specialty See Exclusive Specialty Product List $0.00
Pharmacy Lesser of AWP discount or MRA(as applicable)
Participating Pharmacy Participating Pharmacy Specialty Product List $2.00
Specialty Products Lesser of AWP discount, U&C or MRA(as
applicable)
(b) For Specialty Products needing an additional charge to cover costs of all ASES required to
administer the Specialty Products, the following standard per diem and nursing fee rates shall apply.
Therapeutic Class Brand Name Nursing&Per Diem
Immune Deficiency All $65.00/Infusion
Metabolic Disorder All $65.00/Infusion
PAH Flolan,Veletri and Remodulin $65.00/Day
PAH Epoprostenol Sodium(Generic $65.00/Day
Flolan)
18
221479.v4
PAH Ventavis $65.00/Day
PAH Tyvaso $30.00/Day
Pulmonary All $55.00/Infusion
Nursing Rates All drugs/therapies requiring $150.00 per Initial Visit up to two(2)hours / $75.00
nursing per addt'l hour or a fraction thereof
(c) In no event will the Mail Service Pharmacy or Participating Pharmacy pricing terms specified in
the Agreement, including, but not limited to, the annual average ingredient cost discount guarantees, apply to
Specialty Products.
(d) Unless otherwise set forth in an agreement directly between ESI Specialty Pharmacy and
Sponsor, if a Specialty Product dispensed or ASES provided by ESI Specialty Pharmacy is billed to Sponsor
directly by ESI Specialty Pharmacy instead of being processed through ESI, Sponsor agrees to timely pay ESI
Specialty Pharmacy for such claim pursuant to the rates above and within thirty (30) days of Sponsor's, or its
designee's, receipt of such electronic or paper claim from ESI Specialty Pharmacy. ESI Specialty Pharmacy
shall have 360 days from the date of service to submit such electronic or paper claim.
(e) Notwithstanding the Specialty Product pricing terms set forth above, ESI will guarantee an
average aggregate annual ingredient cost discount for Specialty Product dispensed through ESI Specialty
Pharmacy as follows:
Type of Guarantee ESI Specialty Pharmacy Claims Excluded
Average Aggregate Annual Ingredient AWP-16.50%(1) All Specialty Products Prescription Drug
Cost Discount Guarantee Claims except Specialty Product Prescription
Drug Claims dispensed through ESI Specialty
Pharmacy(excluding Limited Distribution
medications dispensed through ESI Specialty
Pharmacy,which are also excluded)
(1)This guarantee shall only apply if Sponsor elects the ESI Specialty Pharmacy"exclusive"option.
The above Specialty Product guarantee will be reconciled in accordance with the terms of Section I
above.
IV. Vaccine Claims (No vaccine claims will be included in any pricing or rebate guarantee set forth
in the Agreement).
(a) General Terms applicable to Vaccine Claims
(i) Vaccine Claims shall adjudicate at the lower of U&C or the amounts shown in the table below.
In the case of Vaccine Claims, the U&C shall be the retail price charged by a Participating Pharmacy for
the particular vaccine, plus administration and dispensing fees, in a cash transaction on the date the
vaccine is dispensed as reported to ESI by the Participating Pharmacy.
(ii) The Vaccine Administration Fee for Vaccine Claims for Members enrolled in Sponsor's
Medicaid programs, if any, will be capped at the maximum reimbursable amount under the state
Medicaid program in which the Member is enrolled.
(iii) All Vaccine Claims will be subject to any Administrative Fees set forth in the Agreement.
(iv) Vaccine Claims will be charged a program fee of $2.50 per Vaccine Claim. The Vaccine
Program Fee will be billed separately to Sponsor as part of the administrative invoice according to the
billing frequency set forth in this Agreement.
19
221479.v4
(b) Vaccine Claim Pricing
Participating Pharmacy Participating Pharmacy Member Submitted Vaccine
INFLUENZA ALL OTHER VACCINES Claims(excluding foreign
claims)
Vaccine Pass-Through Pass-Through
Administration Fee (capped at$15 per vaccine (capped at$20 per vaccine Submitted amount
claim) claim)
Ingredient Cost Participating Pharmacy Participating Pharmacy
Ingredient Cost as set forth in Ingredient Cost as set forth in the Submitted amount
the Agreement Agreement
Dispensing Fee Participating Pharmacy Participating Pharmacy
Dispensing Fee as set forth in Dispensing Fee as set forth in the Submitted amount
the Agreement Agreement
Administrative Administrative Fee per Prescription Drug Claim as set forth in the Administrative Fee per
FeeNaccine Claim Agreement Prescription Drug Claim(plus
manual claim administrative fee)
as set forth in the Agreement
Vaccine Program $2.50
Fee per vaccine claim
20
221479.v4
Exhibit A-2
Administrative Services and Clinical Program Fees
Commercial Administrative Services
PBM Services–No Additional Fee
Customer service for Members Electronic claims processing
Electronic/on-line eligibility submission Plan setup
Standard coordination of benefits(COB) Software training for access to our on-line system(s)
(reject for primary carrier)
FSA eligibility feeds
Network Pharmacy Services
Pharmacy help desk Pharmacy reimbursement
Pharmacy network management Network development(upon request)
Network Pharmacy Audit Program Network Pharmacy Reporting
Home Delivery Services
Benefit education Prescription delivery–standard
Reporting Services
Web-based client reporting–produced by Sponsor Web-based client reporting–produced by ESI
Ad-hoc desktop parametric reports Annual Strategic Account Plan report
Claims detail extract file electronic(NCPDP format) Billing reports
Load 12 months claims history for clinical reports and reporting Inquiry access to claims processing system
Website Services
Sponsor Website—eService Delivery(Eligibility,Claims,and My Rx Choices–helps members make informed medication
Benefit Administration), Coverage Management and Appeals, choices based on cost, health and safety. Member website
Eligibility File Transfer, Reporting Solutions and Resources portion only.
Area.
Express-Scripts.com for Members—access to benefit,drug, Online Benefit Management–eService web-based
health,and wellness information;prescription ordering application with Claims History, Eligibility Maintenance,and
capability;and customer service. Prior Authorization Add.
Mobile App for Members–includes My Rx Choices, My
Medicine Cabinet, Pharmacy Care Alerts, Refills and
Renewals,and virtual prescription ID card.
Implementation Package and Member Communications
New Member packets(includes two standard resin ID cards) Implementation support
Member replacement cards printed via web
Clinical
Concurrent Drug Utilization Review(DUR) Prior Authorization–Administrative
•Non-clinical Prior Authorization
•Lost/stolen overrides
• Vacation supplies
PBM Services Fees
Manual/hardcopy eligibility submission $10.00/update(includes initial entry)
Member-submitted paper claims processing fee $3.00/claim
Medicaid subrogation claims fee $3.00/claim
Electronic Prescribing Pass-through charge for ePrescribing Eligibility and Formulary
transaction fees charged to Sponsor at ESI's preferred rate
with data switch such as Surescripts.
Reporting Services
Custom ad-hoc reporting $150/hour,with a minimum of$500
Replacement Member Communication Packets
21
221479.v4
PBM Services Fees
Member requested replacement packets $1.50+postage per packet
Sponsor requested re-carding $1.50+postage per packet
Communication Fee
Smart90 and Mail(EHD, SHD&HDE) Programs $2.50 per employee upon implementation of program
(one-time charge)
Reviews and Appeals Management
Initial Determinations(i.e.coverage reviews)and Level One Included in the existing UM PMPM charge
Appeals for the Coverage Authorization Program,consisting
of:
• Prior Authorization
• Step Therapy
• Drug Quantity Management
Initial Determinations and Level One Appeals for the Benefit $55 per review
Review Program,consisting of reviews known as:
• Plan Design Related Requests
• Plan Exclusion Reviews(clinical or administrative reviews
of non-covered drugs)
• Copay Reviews
• Plan Limit Reviews(e.g.age,gender,days'supply limits)
• Plan Rule/Administrative Reviews/Non-clinical Reviews
• Clinical Benefit Reviews
• Direct Claim Reject Reviews
Final and Binding Appeals—Level Two Appeals*and/or Urgent $10.00 per review*(incremental to PMPM fees or per review
Appeals*" fees above)
*Level One for clients with only one level of appeal *this additional fee is applied to each initial
**Appeals can be urgent at Level One or Level Two and determination.
decisions are final and binding.
External Reviews by Independent Review Organizations-for $800 per review
non-grandfathered plans
Comprehensive Consumer Driven Health(CDH)Solution
Required Services and Fee for all CDH enrolled Members
Foundational Services Technical and Member Advocacy:$0.35 PMPM
• Technical
Bi-directional data exchange;dedicated operations;24-hour a
day,seven-days a week monitoring and quality control;
performance reporting;and analytics
• Member Advocacy
Dedicated CDH member services, My Rx Choices Plus,open Additional services will be quoted upon request.
enrollment tools and member communications library, robust Postage charges are not included and will be billed to
online features,and preventive care Sponsor.
Optional Service and Fee for all CDH enrolled Members
Comprehensive Member Engagement Services Comprehensive Services:$0.30 PMPM
• Health Choices
Medication Adherence Monitoring and Outreach and proactive, All Services(Foundational&Comprehensive):$0.65 PMPM
personalized member communications
• Drug Choices
Benefit Coaching, Prescription Benefit Review Statements, Additional services will be quoted upon request.
proactive,personalized member communications Postage charges are not included and will be billed to
Sponsor.
Required Service and Fee for all Non-CDH enrolled
Members—If Sharing Data Only
22
221479.v4
PBM Services Fees
Combined Benefit Management $0.10 PMPM per combined accumulator up to maximum of
Services to manage combined medical-pharmacy benefits that $0.20 PMPM for existing connection with medical carrier or
are not a consumer-directed health(CDH)plan. TPA.
Services include ongoing management of the data exchange Fees to establish connection with new medical carrier or TPA
platform with the medical vendor/TPA, production monitoring will be quoted upon request.
and quality control,and dedicated operations team. Combined Additional services will be quoted upon request.
benefit types may include deductible,out of pocket,spending Postage charges are not included and will be billed to
account,and lifetime maximum. Sponsor.
Medicare Part D—Retiree Drug Subsidy(RDS)
RDS enhanced service(ESI sends reports to CMS on behalf of $1.12 PMPM for Medicare-qualified Members with a minimum
Sponsor) annual fee of$7,500
• Notice of Creditable Coverage $1.35/letter+postage
RDS standard service(ESI sends reports to Sponsor) $0.62 PMPM for Medicare-qualified Members with a minimum
annual fee of$5,000
• Notice of Creditable Coverage $1.35/letter+postage
Electronic Medicare Part D EOB
Electronic Medicare EOB is an e-mail notification to the $0.15/per EOB
Member informing them at the time of EOB production that
their Medicare Part D Explanation of Benefits is available for
viewing. Members can opt in/opt out at any time.
Electronic EOB includes:
• Email notification to the Member
• Solicitation e-mail sent to registered Members
• Prominent Web messaging
Cost Exceeds Maximum
ESI-Managed Cost Exceeds Maximum(CEM)edit $10,000 CEM limit—included in pricing
(For non-compound drugs) Custom CEM limit less than$10,000-$0.01 PMPM fee
ESI-Managed Cost Exceeds Maximum(CEM)edit Included in pricing
(For compound drugs)
Client Managed Cost Exceeds Maximum(CEM)edit Included in pricing
(For non-compound and compound drugs)
II. Clinical/Trend Programs.
ESI offers a comprehensive suite of trend and integrated health management programs. These offerings may
change or be discontinued from time to time as ESI updates its offerings to meet the needs of the marketplace.
The programs (and corresponding pricing and guarantees) outlined in the Clinical Addendum (executed
separately by Sponsor) represent the programs currently adopted by Sponsor as of the Effective Date. ESI also
offers additional programs, as well as savings guarantees, under certain conditions. Information concerning
such programs, guarantees, and fees, if applicable, is available on request. In addition, the ESI Account
Management Team will periodically discuss new programs, guarantees, and fees with Sponsor, which Sponsor
may adopt through ESI's standard Set-Up Form process.
Sponsor will select clinical/trend programs during implementation by checking selected options on the Clinical
Addendum and on the applicable Set-Up Form. Such Set-Up Forms are incorporated herein by reference as
and when executed by the parties.
Please refer to the Clinical Addendum for a listing of Sponsor's programs.
23
221479.v4
EXHIBIT A-3
Rebates
(Does Not Apply to Specialty Products)
1. Rebate Amounts
A. Subject to the conditions set forth in Sections 2. — 4. below and elsewhere in this Agreement, ESI
will pay to Sponsor an amount equal to the greater of:
(i) 80% of the Rebates and Manufacturer Administrative Fees received by ESI, excluding Rebates
received by ESI for Specialty Products;
Or
(ii) Subject to Sponsor meeting the Plan design conditions identified in the table below, the
following guaranteed amounts, excluding claims for Specialty Products:
Formulary: ESI National Preferred
Copayment Design: Minimum$15 Copayment Differential
Participating Mail Service Mail Service
Pharmacies Pharmacy Pharmacy
(1-45 days'supply) (46-90 days'supply)
Per Brand Claim
Year 1 $56.97 $56.97 $178.49
Year 2 $70.86 $70.86 $217.18
Year 3 $87.41 $87.41 $268.59
B. If the Plan design conditions identified in the table in Section 1.A.(ii) above are not met, the "greater
of' methodology and the guaranteed amounts shall not apply, and ESI will, subject to the remaining
terms of this Agreement, pay Sponsor Rebate amounts pursuant to the percentage set forth in Section
1.A.(i) above.
2. Exclusions
Member Submitted Claims, Specialty Products, Subrogation Claims, biosimilar products, OTC products,
claims older than 180 days, claims through Sponsor-owned, in-house, or on-site pharmacies, 340b
pharmacies, and claims pursuant to a 100% Member Copayment plan are not eligible for the
guaranteed Rebate amounts set forth in Section 1.A.(ii) above.
3. Rebate Payment Terms
A. Subject to the conditions set forth herein, ESI shall pay Sponsor the percentage amount set forth in
Section 1.A.(i) above for Rebates and Manufacturer Administrative Fees collected by ESI during
each calendar quarter hereunder within approximately one hundred and fifty (150) days following
the end of such calendar quarter. ESI shall also pay Sponsor the percentage amount set forth in
Section 1.A.(i) above for residual Rebates and Manufacturer Administrative Fees collected by ESI, if
any, related to such calendar quarter, which are collected by ESI in subsequent quarters.
B. On an annual and aggregate basis, ESI shall reconcile the guaranteed amounts set forth in Section
1.A.(ii) above (against the percentage amount paid to Sponsor quarterly) within two hundred and
forty (240) days following the end of each calendar year and shall credit Sponsor for any deficit on
the next invoice immediately following the reconciliation to the extent such deficit is not offset by ESI
against excesses achieved in other guarantees offered pursuant to this Agreement. If, upon
24
221479.v4
reconciliation, the annual aggregate percentage amount paid to Sponsor for the calendar year
pursuant to Section 1.A.(i) and 3.A. above is greater than the guaranteed aggregate amounts set
forth in Section 1.A.(ii) above, ESI shall be entitled to make up for, and offset, a shortfall in other
Rebate guarantee(s) set forth in this Agreement with such excess annual aggregate percentage
amount, and such excess amount shall be applied either directly to the other shortfall in a Rebate
guarantee(s) or applied as a credit against future Rebate payments and Manufacturer
Administrative Fee payments (or as a direct invoice amount to be paid by Sponsor, if a credit is not
feasible).
4. Conditions
A. ESI contracts for Rebates and Manufacturer Administrative Fees on its own behalf and for its own
benefit, and not on behalf of Sponsor. Accordingly, ESI retains all right, title and interest to any and
all actual Rebates and Manufacturer Administrative Fees received. ESI will pay Sponsor amounts
equal to the Rebate and Manufacturer Administrative Fees amounts allocated to Sponsor, as
specified above, from ESI's general assets (neither Sponsor, its Members, nor Sponsor's plan
retains any beneficial or proprietary interest in ESI's general assets). Sponsor acknowledges and
agrees that neither it, its Members, nor its Plan will have a right to interest on, or the time value of,
any Rebate payments or Manufacturer Administrative Fee payments received by ESI during the
collection period or moneys payable under this Section. No amounts for Rebates or Manufacturer
Administrative Fees will be paid until this Agreement is executed by Sponsor. ESI will have the right
to apply Sponsor's allocated Rebate amount and Manufacturer Administrative Fees amount to
unpaid Fees.
B. Sponsor acknowledges that it may be eligible for Rebate amounts and Manufacturer Administrative
Fee amounts under this Agreement only so long as Sponsor, its affiliates, or its agents do not
contract directly or indirectly with anyone else for discounts, utilization limits, rebates or other
financial incentives on pharmaceutical products or formulary programs for claims processed by ESI
pursuant to the Agreement, without the prior written consent of ESI. In the event that Sponsor
negotiates or arranges for Rebates or similar discounts for any Covered Drugs hereunder, but
without limiting ESI's right to other remedies, ESI may immediately withhold any Rebate amounts or
Manufacturer Administrative Fee amounts earned by, but not yet paid to, Sponsor as necessary to
prevent duplicative rebates on Covered Drugs. To the extent Sponsor knowingly negotiates and/or
contracts for discounts or rebates on claims for Covered Drugs without prior written approval of ESI,
such activity will be deemed to be a material breach of this Agreement, entitling ESI to suspend
payment of Rebate amounts and Manufacturer Administrative Fee amounts hereunder and to
renegotiate the terms and conditions of this Agreement.
C. Under its Rebate program, ESI may implement ESI's Formulary management programs and
controls, which may include, among other things, cost containment initiatives, and communications
with Members, Participating Pharmacies, and/or physicians. ESI reserves the right to modify or
replace such programs from time to time. Guaranteed Rebate amounts, if any, set forth herein, are
conditioned on adherence to various Formulary management controls, benefit design requirements,
claims volume, and other factors stated in the applicable pharmaceutical manufacturer agreements,
as communicated by ESI to Sponsor from time to time. If any government action, change in law or
regulation, change in the interpretation of any law or regulation, or any action by a pharmaceutical
manufacturer has an adverse effect on the availability of Rebates, then ESI may make an
adjustment to the Rebate terms and guaranteed Rebate amounts, if any, hereunder.
D. Rebate and Manufacturer Administrative Fee amounts paid to Sponsor pursuant to this Agreement
are intended to be treated as "discounts" pursuant to the federal anti-kickback statute set forth at 42
U.S.C. §1320a-7b and implementing regulations. Sponsor is obligated if requested by the
Secretary of the United States Department of Health and Human Services, or as otherwise required
by applicable law, to report the Rebate amounts and to provide a copy of this notice. ESI will refrain
from doing anything that would impede Sponsor from meeting any such obligation.
25
221479.v4
EXHIBIT A-4
Rebates (Specialty Products)
1. Rebate Amounts
Subject to: (i) the conditions set forth in Sections 2. —4. below and elsewhere in this Agreement; and (ii)
Sponsor meeting the Plan design conditions identified in the table below, ESI will pay to Sponsor the
following guaranteed amounts:
Formulary: ESI National Preferred
Copayment Design: Minimum$15 Copayment Differential
Participating ESI Specialty ESI Specialty
Pharmacies Pharmacy Pharmacy
(1-45 days'supply) (46-90 days'supply)
Per Brand Claim $50.00 $125.00 $125.00
2. Exclusions
Member Submitted Claims, Subrogation Claims, biosimilar products, OTC products, claims older than
180 days, claims through Sponsor-owned, in-house, or on-site pharmacies, 340b pharmacies, and
claims pursuant to a 100% Member Copayment plan are not eligible for the guaranteed Rebate
amounts set forth in Section 1.A.(ii) above.
3. Rebate Payment Terms
Subject to the conditions set forth herein, ESI shall pay Sponsor the guaranteed amounts set forth in
Section 1 above within approximately one hundred and fifty (150) days following the end of each
calendar quarter for utilization occurring during such quarter.
4. Conditions
A. ESI contracts for Rebates on its own behalf and for its own benefit, and not on behalf of Sponsor.
Accordingly, ESI retains all right, title and interest to any and all actual Rebates received. ESI will
pay Sponsor amounts equal to the Rebate amounts allocated to Sponsor, as specified above, from
ESI's general assets (neither Sponsor, its Members, nor Sponsor's plan retains any beneficial or
proprietary interest in ESI's general assets). Sponsor acknowledges and agrees that neither it, its
Members, nor its Plan will have a right to interest on, or the time value of, any Rebate payments
received by ESI during the collection period or moneys payable under this Section. No amounts for
Rebates will be paid until this Agreement is executed by Sponsor. ESI will have the right to apply
Sponsor's allocated Rebate amount to unpaid Fees.
B. Sponsor acknowledges that it may be eligible for Rebate amounts under this Agreement only so
long as Sponsor, its affiliates, or its agents do not contract directly or indirectly with anyone else for
discounts, utilization limits, rebates or other financial incentives on pharmaceutical products or
formulary programs for claims processed by ESI pursuant to the Agreement, without the prior
written consent of ESI. In the event that Sponsor negotiates or arranges for Rebates or similar
discounts for any Covered Drugs hereunder, but without limiting ESI's right to other remedies, ESI
may immediately withhold any Rebate amounts earned by, but not yet paid to, Sponsor as
necessary to prevent duplicative rebates on Covered Drugs. To the extent Sponsor knowingly
negotiates and/or contracts for discounts or rebates on claims for Covered Drugs without prior
26
221479.v4
written approval of ESI, such activity will be deemed to be a material breach of this Agreement,
entitling ESI to suspend payment of Rebate amounts hereunder and to renegotiate the terms and
conditions of this Agreement.
C. Under its Rebate program, ESI may implement ESI's Formulary management programs and
controls, which may include, among other things, cost containment initiatives, and communications
with Members, Participating Pharmacies, and/or physicians. ESI reserves the right to modify or
replace such programs from time to time. Guaranteed Rebate amounts, if any, set forth herein, are
conditioned on adherence to various Formulary management controls, benefit design requirements,
claims volume, and other factors stated in the applicable pharmaceutical manufacturer agreements,
as communicated by ESI to Sponsor from time to time. If any government action, change in law or
regulation, change in the interpretation of any law or regulation, or any action by a pharmaceutical
manufacturer has an adverse effect on the availability of Rebates, then ESI may make an
adjustment to the Rebate terms and guaranteed Rebate amounts, if any, hereunder.
D. Rebate amounts paid to Sponsor pursuant to this Agreement are intended to be treated as
"discounts" pursuant to the federal anti-kickback statute set forth at 42 U.S.C. §1320a-7b and
implementing regulations. Sponsor is obligated if requested by the Secretary of the United States
Department of Health and Human Services, or as otherwise required by applicable law, to report the
Rebate amounts and to provide a copy of this notice. ESI will refrain from doing anything that would
impede Sponsor from meeting any such obligation.
27
221479.v4
EXHIBIT B
AUDIT PROTOCOL
1. AUDIT PRINCIPLES
ESI recognizes the importance of its clients ensuring the integrity of their business relationship by engaging in annual
audits of their financial arrangements with ESI, and, where applicable (i.e., Medicare Part D), by auditing compliance
with applicable regulatory requirements. ESI provides this audit right to each and every client. In granting this right,
ESI's primary interest is to facilitate a responsive and responsible audit process. In order to accomplish this goal, for all
clients, ESI has established the following Protocol. Our intent is in no way to limit Sponsor's ability to determine that ESI
has properly and accurately administered the financial aspects of the Agreement or complied with applicable regulatory
requirements, but rather to create a manageable process in order to be responsive to our clients and the independent
auditors that they may engage.
ESI strongly encourages clients to have their auditors, without jeopardizing the independent nature of the audit, review
the auditor's initial findings and reports with ESI prior to discussing with the client in order to avoid any unnecessary
client confusion. In addition, clients should not initiate a new audit until all parties have agreed that the prior audit is
closed. We have found often times that items identified as issues during the initial audit turn out to be non-findings once
a dialogue takes place between the auditor and ESI. In other words,we believe it is in everyone's interest to ensure that
the auditor and ESI are not simply"missing each other" in the exchange of information prior to the auditor reviewing its
findings with the client.
2. AUDIT PREREQUISITES
A. There are four components of your arrangement with ESI eligible for audit on an annual basis from February
through October:
• Retrospective Claims
• Rebates
• Performance Guarantees
• Compliance with Regulatory Requirements(i.e., Medicare Part D)
Balancing the need to adequately support the audit process for all ESI clients, with an efficient allocation of
resources, we encourage clients to audit all four components, as applicable, through a single annual audit. If you
choose to audit the above components separately throughout the year, rather than combining all components into a
single annual audit, you will be subject to ESI's standard charges for each additional audit. All such fees shall be
reasonable and based on ESI's costs for supporting such additional audits.
B. ESI will provide all data reasonably necessary for Sponsor to determine that ESI has performed in accordance with
contractual terms. ESI will use commercially reasonable best efforts to provide the retrospective claims and benefit
information in no more than fifteen (15) days from audit kickoff call and having an executed confidentiality
agreement. Our pledge to respond within the foregoing timeframe is predicated on a good faith and cooperative
effort between Sponsor and/or its Auditor and ESI.
C. ESI engages a national accounting firm, at its sole cost and expense, to conduct a SSAE 16 audit on behalf of its
clients. Upon request, ESI will provide the results of its most recent SSAE 16 audit. Testing of the areas covered
by the SSAE 16 is not within the scope of Sponsor's audit rights (i.e., to confirm the financial aspects of the
Agreement) and is therefore not permitted. However, if requested, ESI will explain the SSAE 16 audit process and
findings to Sponsor in order for Sponsor to gain an understanding of the SSAE 16.
3. AUDITS
A. ESI recommends that the initial audit period for a claims audit cover a timeframe not to exceed twenty-four (24)
months immediately preceding the request to audit (the "Audit Period"). This Audit Period allows a reasonable
amount of time for both parties to conclude the audit before claims data is archived off the adjudication system. ESI
will accommodate reasonable requests to extend the Audit Period, but this may delay ESI's response time to audit
findings due to the age of the claims. Due to the additional resources necessary to pull claims data older than
twenty-four(24) months, if you request to extend the Audit Period, you will be subject to ESI's standard charges for
such additional data pulls. All such fees shall be reasonable and based on ESI's additional costs associated with
retrieval and reporting of such data. If the parties mutually determine, acting in good faith, that the initial audit
demonstrates in any material respects that ESI has not administered the financial arrangement consistent with the
contract terms of the Agreement, then ESI will support additional auditing beyond the Audit Period at no additional
charge.
B. CMS generally modifies its requirements for administering the Medicare Part D annually. For this reason, ESI
recommends that the initial audit period for a Medicare Part D compliance audit cover a timeframe not to exceed
the twelve(12) months immediately preceding the request to audit(collectively,the"Medicare Part D Audit Period").
This Medicare Part D Audit Period is intended to assist our clients with the CMS annual oversight requirements.
Due to the additional resources necessary to pull data older than twelve (12) months, if you request to extend the
28
221479.v4
Audit Period, you will be subject to ESI's standard charges for such additional data pulls. All such fees shall be
reasonable and based on ESI's additional costs associated with retrieval and reporting of such data.
C. When performing a Rebate audit, Sponsor may perform an on-site review of the applicable components of
manufacturer agreements, selected by Sponsor, as reasonably necessary to audit the calculation of the Rebate
payments made to Sponsor by ESI. Our ability to drive value through the supply chain and in our negotiations with
manufacturers is dependent upon the strict confidentiality and use of these agreements. Providing access to these
agreements to third parties that perform services in the industry beyond traditional financial auditing jeopardizes our
ability to competitively drive value. For this reason, unless otherwise agreed by the Parties, access to and audit of
manufacturer agreements is restricted to a mutually agreed upon CPA accounting firm whose audit department is a
separate stand-alone division of the business, which carries insurance for professional malpractice of at least Two
Million Dollars($2,000,000).
D. ESI recommends that Sponsor select an initial number of manufacturer contracts to enable Sponsor to audit fifty
percent (50%) of the total Rebate payments due to Sponsor for two (2) calendar quarters during the twelve (12)
month period immediately preceding the audit (the "Rebate Audit Scope and Timeframe"). ESI will accommodate
reasonable requests to extend this Rebate Audit Scope and Timeframe, but this may delay ESI's on-site
preparation time as well as response time to audit findings. Due to the additional resources necessary to support a
Rebate audit beyond the Rebate Audit Scope and Timeframe, if you request to extend the Rebate Audit Scope and
Timeframe, you will be subject to ESI's standard charges for such additional audit support. All such fees shall be
reasonable and based on ESI's additional costs. If the parties mutually determine, acting in good faith, that the
initial Rebate audit demonstrates in any material respects that ESI has not administered Rebates consistent with
the contract terms of the Agreement, then ESI will support additional auditing beyond the Rebate Audit Scope and
Timeframe at no additional charge.
E. If you have a Pass-Through pricing arrangement for Participating Pharmacy claims, ESI will provide the billable and
payable amount for a sampling of claims provided by you or your auditor (i.e., ESI will provide the actual
documented claim record) during the audit to verify that ESI has administered such Pass-Through pricing
arrangement consistent with the terms of the Agreement. If further documentation is required, ESI may provide a
statistically valid sample of claims remittances to the Participating Pharmacies to demonstrate ESI's administration
of Pass-Through pricing. In any instance where the audit demonstrates that the amount billed to you does not
equal the Pass-Through amount paid to the Participating Pharmacy, you or your auditor may perform an on-site
audit of the applicable Participating Pharmacy contract rate sheet(s).
4. AUDIT FINDINGS
A. Following Sponsor's initial audit, Sponsor(or its Auditor)will provide ESI with suspected errors, if any. In order for
ESI to evaluate Sponsor's suspected errors, Sponsor shall provide an electronic data file in a mutually agreed upon
format containing up to 300 claims for further investigation by ESI. ESI will use commercially reasonable best efforts
to respond to the suspected errors in no more than sixty (60) days from ESI's receipt of such findings. Our pledge
to respond within the foregoing timeframe is predicated on a good faith and cooperative effort between Sponsor
and/or its Auditor and ESI.
B. Following Sponsor's initial audit of Medicare Part D compliance, Sponsor (or its Auditor) will provide ESI with a
written report of suspected non-compliant issues, if any. In order for ESI to evaluate Sponsor's suspected errors,
Sponsor shall provide ESI with specific regulatory criteria and Medicare Part D program requirements used to cite
each suspected non-compliant and payment reconciliation issue. ESI will use commercially reasonable best efforts
to respond to the audit report in no more than thirty (30) days from ESI's receipt of the report. Please be aware,
however, that audits that require evaluation of six (6) or more findings typically require additional time to respond.
Our pledge to respond within the foregoing timeframe is predicated on a good faith and cooperative effort between
Sponsor and/or its Auditor and ESI.
C. Upon receipt and review of ESI's responses to Sponsor(or its Auditor), Sponsor(or its Auditor)will provide ESI with
a written report of draft findings and recommendations. ESI will use commercially reasonable best efforts to
respond to the audit report in no more than fifteen (15)days from ESI's receipt of the report. Our pledge to respond
within the foregoing timeframe is predicated on a good faith and cooperative effort between Sponsor and/or its
Auditor and ESI.
D. Sponsor agrees that once audit results are accepted by both parties, the audit shall be considered closed and final.
To the extent the mutually accepted audit results demonstrate claims errors, ESI will reprocess the claims and
make corresponding adjustments to Sponsor through credits to a future invoice(s). If we are unable to reprocess
claims and issue corresponding credits to Sponsor through this process, ESI will make adjustments to Sponsor via
a check or credit.
5. AUDITS BY GOVERNMENT ENTITIES
A. In the event CMS, the OIG, MEDIC, or another government agency has engaged in an audit of Sponsor and/or its
"first tier" and "downstream entities", Sponsor shall contact the ESI Account Management team and provide a
written copy of the audit notice or request from the government agency promptly upon receipt.
29
221479.v4
B. Sponsor agrees that CMS may have direct access to ESI's and any such "downstream entity's" pertinent contracts,
books, documents, papers, records, premises and physical facilities, and that ESI and such "downstream entity"will
provide requested information directly to CMS unless otherwise agreed upon by ESI and Sponsor.
C. Following the government audit of Sponsor and its "first tier" and "downstream entities", Sponsor shall provide ESI
with a written report of suspected non-compliant issues noted in the government audit that relate to services
provided by ESI, if any. If there are such findings, ESI will work with Sponsor and/or government agency to
respond to any suspected non-compliant issues.
D. Support for all such audits by government entities will be subject to ESI's standard charges. All such fees shall be
reasonable and based on ESI's costs for supporting such audits.
6. CONFIDENTIALITY
ESI's contracts are highly confidential and proprietary. For this reason, ESI only permits on-site review rather than provide
copies to our clients. During on-site contract review, Sponsor (or its Auditor) may take and retain notes to the extent
necessary to document any identified errors, but may not copy (through handwritten notes or otherwise) or retain any
contracts (in part or in whole) or related documents provided or made available by ESI in connection with the audit. ESI will
be entitled to review any notes to affirm compliance with this paragraph.
30
221479.v4
EXHIBIT C
BUSINESS ASSOCIATE AGREEMENT
Express Scripts, Inc. and one or more of its subsidiaries ("ESI"), and Sponsor or one of its affiliates ("Sponsor"), are parties
to an agreement("PBM Agreement")whereby ESI provides certain pharmacy benefit management services to the Sponsor's
prescription drug plan (Sponsor and Sponsor's prescription drug plan collectively referred to hereinafter as"Plan"). The PBM
Agreement addresses the parties' rights and obligations concerning the use and disclosure of patients' protected health
information. The HIPAA Rules (as defined below) require ESI and Plan to enter into a "business associate agreement" to
comply with applicable sections of the HIPAA Rules.
1. Definitions.
(a) "Breach"shall have the same meaning as the term"breach"in 45 C.F.R. § 164.402.
(b) "Designated Record Set" shall have the same meaning as the term "designated record set" in 45 C.F.R. §
164.501.
(c) "Electronic Health Record" shall mean an electronic record of health-related information on an Individual
that is created, gathered, managed, and consulted by authorized health care clinicians and staff.
(d) "Electronic PHI" shall have the same meaning as the term "electronic protected health information" in 45
C.F.R. § 160.103.
(e) "HIPAA Rules" means the collective privacy, transaction and code sets, and security regulations
promulgated pursuant to the Health Insurance Portability and Accountability Act, as codified at 45 C.F.R. Parts 160, 162 and
164, as amended from time to time.
(f) "Individual"shall have the same meaning as the term "individual" in 45 C.F.R. § 160.103 and shall include
a person who qualifies as a personal representative in accordance with 45 C.F.R. § 164.502(g).
(g) "Privacy Rule" shall mean the Standards for Privacy of Individually Identifiable Health Information at 45
C.F.R. Part 160 and 45 C.F.R. Part 164, Subpart A and Subpart E, as amended from time to time.
(h) "Protected Health Information" or "PHI" shall have the same meaning as the term "protected health
information"in 45 C.F.R. § 160.103, limited to the information created or received by ESI from or on behalf of Plan.
(i) "Required by Law"shall have the same meaning as the term"required by law"in 45 C.F.R. § 164.103.
(i) "Secretary" shall mean the Secretary of the Department of Health and Human Services or his/her
designee.
(k) "Security Incident"shall have the same meaning as"security incident"in 45 C.F.R. § 164.304
(I) "Security Standards" shall mean the Security Standards, 45 C.F.R. Part 164, Subpart C, as amended from
time to time.
(m) "Transactions Standards" shall mean the Standards for Electronic Transactions, 45 C.F.R. Part 162,
Subpart I, as amended from time to time.
(n) "Unsecured PHI"shall have the same meaning as the term"unsecured protected health information"in 45
C.F.R. § 164.402.
Capitalized terms used, but not otherwise defined, in this Business Associate Agreement shall have the same
meaning as those terms in the HIPAA Rules.
2. General Use and Disclosure Provisions. ESI and Plan acknowledge and agree as follows:
(a) Use or Disclosure. ESI agrees not to use or further disclose PHI other than as expressly permitted or
required by this Business Associate Agreement or the HIPAA Rules or as Required by Law.
(b) Minimum Necessary. ESI will take reasonable efforts to limit requests for, use and disclosure of PHI to the
minimum necessary to accomplish the intended request, use or disclosure.
31
221479.v4
(c) Specific Use or Disclosure Provisions. Except as otherwise limited in this Business Associate Agreement,
ESI may use and disclose PHI to properly provide, manage and administer the services required under the PBM Agreement
and consistent with applicable law to assist Plan in its operations, as long as such use or disclosure would not violate the
HIPAA Rules if done by Plan,or such use or disclosure is expressly permitted in (i)through(iii) below:
(i) ESI may use PHI for the proper management and administration of ESI or to carry out ESI's legal
responsibilities.
(ii) ESI may disclose PHI to third parties for the proper management and administration of ESI or to
carry out the legal responsibilities of ESI provided that the disclosures are Required by Law, or
ESI obtains reasonable assurances from the person to whom the information is disclosed that:
(A) the information will remain confidential, (B) the information will be used or further disclosed
only as Required by Law or for the purpose for which it was disclosed to the person, and (C)the
person notifies ESI of any instances of which it is aware in which the confidentiality of the
information has been breached.
(iii) ESI may use PHI to perform Data Aggregation services on behalf of Plan as permitted by 45
C.F.R. § 164.504(e)(2)(i)(B).
(d) Reporting. ESI agrees to promptly notify the Plan if ESI has knowledge that PHI has been used or
disclosed by ESI in a manner that violates this Business Associate Agreement. To the extent that ESI creates, receives,
maintains or transmits Electronic PHI, ESI agrees to report promptly to the Plan any Security Incident, as determined by ESI,
involving PHI of which ESI becomes aware. ESI shall comply with 45 C.F.R. § 164.402 and shall, following the discovery of
a Breach of Unsecured PHI, notify the Plan of such Breach, in accordance with 45 C.F.R. § 164.410.
(e) Safeguards. ESI agrees to use appropriate safeguards, consistent with applicable law, to prevent use or
disclosure of PHI in a manner that would violate this Business Associate Agreement. ESI shall provide Plan with such
information concerning such safeguards as Plan may reasonably request from time to time. To the extent that ESI creates,
receives, maintains or transmits Electronic PHI, ESI agrees to use appropriate administrative, physical and technical
safeguards, and comply with the Security Standards, to protect the confidentiality, integrity and availability of the Electronic
PHI that ESI creates, receives, maintains or transmits on behalf of Plan.
(f) Mitigation. ESI agrees to mitigate, to the extent practicable, any harmful effect that is known to ESI of a
use or disclosure of PHI by ESI in violation of this Business Associate Agreement or the PBM Agreement.
(g) Subcontractors and Agents. ESI agrees to ensure that any agent, including a Subcontractor, to whom it
provides PHI received from, or created or received by ESI on behalf of Plan, agrees, in writing, to the same restrictions,
terms and conditions that apply through this Agreement to ESI with respect to such information, including the requirement
that it implement reasonable and appropriate safeguards and comply with Subpart C of 45 C.F.R. Part 164, to protect any
Electronic PHI that is disclosed to it by ESI.
(h) Access. Within fifteen (15) business days of a request by Plan, ESI shall provide access to Plan to PHI in
a Designated Record Set in order to meet the requirements under 45 C.F.R. § 164.524. If ESI receives a request directly
from an Individual, or if requested by Plan that access be provided to the Individual, ESI shall provide access to the
Individual to PHI in a Designated Record Set within thirty (30) days in order to meet the requirements under 45 C.F.R. §
164.524.
(i) Amendment. Within sixty (60) days of a request by Plan or subject Individual, ESI agrees to make any
appropriate amendment(s) to PHI in a Designated Record Set that Plan directs or agrees to pursuant to 45 C.F.R. §
164.526.
(t) Accounting. Within thirty (30) days of a proper request by Plan, ESI agrees to document and make
available to Plan, for a reasonable cost-based fee (under conditions permitted by HIPAA if an Individual requests an
accounting more than once during a twelve month period), such disclosures of PHI and information related to such
disclosures necessary to respond to such request for an accounting of disclosures of PHI, in accordance with 45 C.F.R. §
164.528. Within sixty (60) days of proper request by subject Individual, ESI agrees to make available to the Individual the
information described above. ESI shall retain copies of any accountings for a period of six (6) years from the date the
accounting was created.
(k) Restrictions on Use or Disclosure. Within fifteen (15) business days of a request of Plan, ESI agrees to
consider restrictions on the use or disclosure of PHI agreed to by Plan on behalf of an Individual in accordance with 45
C.F.R. § 164.522.
32
221479.v4
(I) Audit and Inspection. ESI agrees to make internal practices, books, and records relating to the use and
disclosure of PHI received from, or created or received by ESI on behalf of Plan, available to Plan within ten (10) business
days, or at the request of Plan or the Secretary, to the Secretary in a time and manner directed by the Secretary, for
purposes of the Secretary determining Plan's compliance with the HIPAA Rules. Any release of information regarding ESI's
practices, books and records is proprietary to ESI and shall be treated as confidential and shall not be further disclosed
without the written permission of ESI, except as necessary to comply with the HIPAA Rules.
(m) Privacy of Individually Identifiable Health Information. To the extent ESI is to carry out one or more of
Plan's obligations under Subpart E of 45 C.F.R. Part 164, ESI agrees to comply with the requirements of subpart E that
apply to the covered entity in the performance of such obligations.
3. Plan Obligations.
(a) Plan shall notify ESI of any limitation(s) in the notice of privacy practices of Plan in accordance with 45
C.F.R. § 164.520,to the extent that such limitation may affect ESI's use or disclosure of PHI.
(b) Plan shall notify ESI of any changes in, or revocation of, permission by an Individual to use or disclose
PHI,to the extent that such changes may affect ESI's use or disclosure of PHI.
(c) Plan shall notify ESI of any restriction to the use or disclosure of PHI that Plan has agreed to in
accordance with 45 C.F.R.§ 164.522,to the extent that such restriction may affect EST's use or disclosure of PHI.
(d) Plan shall not request that ESI use or disclose PHI in any manner that would exceed that which is
minimally necessary under the HIPAA Rules or that would not be permitted by a Covered Entity.
(e) Plan agrees that it will have entered into "Business Associate Agreements" with any third parties (e.g.,
case managers, brokers or third party administrators)to which Plan directs and authorizes ESI to disclose PHI.
4. Transactions Standards. The HIPAA Rules provide for certain Transactions Standards for transfer of data
between trading partners. While certain of the standards may or may not be adopted by Plan (e.g.,for eligibility), ESI will be
prepared to accept the following in accordance with 45 C.F.R. Part 162.1502: ASC X1 2N 834 — Benefit Enrollment and
Maintenance. In addition, to the extent applicable, ESI shall comply with other applicable transactions standards for claims
processing functions between ESI and provider pharmacies. Each party hereby agrees that it shall not change any
definition, data condition or use of a data element or segment in a standard, add any data elements or segment to the
maximum defined data set, use any code or data elements that are either marked "not used" in the standard's
implementation specification or are not in the implementation specification, or change the meaning or intent of the
implementation specification.
5. Material Breach of Business Associate Agreement; Termination.
(a) Without limiting the termination rights of the parties pursuant to the PBM Agreement, upon either party's
knowledge of a material breach by the other of this Business Associate Agreement, the non-breaching party shall notify the
breaching party of such material breach and the breaching party shall have thirty(30) days to cure such material breach. In
the event the breach is not cured, or cure is infeasible, the non-breaching party shall have the right to immediately terminate
this Business Associate Agreement and the PBM Agreement or if cure of the material breach is infeasible, report the
violation to the Secretary.
(b) To the extent feasible, upon termination of the PBM Agreement for any reason, ESI shall, and shall cause
any subcontractors and agents to, return or destroy and retain no copies of all PHI received from, or created or received by
ESI on behalf of, Plan. If ESI determines, in its sole discretion, that return or destruction of such information is not feasible,
ESI shall continue to limit the use or disclosure of such information as set forth in this Agreement as if the PBM Agreement
had not been terminated.
6. Miscellaneous.
(a) Amendment. The parties acknowledge that the foregoing provisions are designed to comply with the
mandates of the HIPAA Rules. ESI shall provide written notice to Plan to the extent that any regulation or amendment to
regulations promulgated by the Secretary requires changes to this Business Associate Agreement. Such written notice shall
include any additional amendment required by any such final regulation and the Business Associate Agreement shall be
automatically amended to incorporate the changes set forth in such amendment provided by ESI to Plan, unless Plan objects
to such amendment in writing within fifteen (15)days of receipt of such written notice. In the event that Plan objects timely to
such amendment, the parties shall work in good faith to reach agreement on an amendment to the Business Associate
Agreement that complies with the final regulations. If the parties are unable to reach agreement regarding an amendment to
the Business Associate Agreement within thirty(30)days of the date that ESI receives any written objection from Plan, either
33
221479.v4
ESI or Sponsor may terminate this Business Associate Agreement upon ninety (90) days written notice to the other party.
Any other amendment to this Business Associate Agreement unrelated to compliance with applicable law and regulations
shall be effective only upon execution of a written agreement between the parties.
(b) Effect on PBM Agreement. Except as relates to the use, security and disclosure of PHI and electronic
transactions, this Business Associate Agreement is not intended to change the terms and conditions of, or the rights and
obligations of the parties under,the PBM Agreement.
(c) No Third-Party Beneficiaries. Nothing express or implied in the PBM Agreement or in this Business
Associate Agreement is intended to confer, nor shall anything herein confer, upon any person other than the parties and the
respective successors or assigns of the parties,any rights, remedies, obligations or liabilities whatsoever.
(d) Interpretation. Any ambiguity in this Business Associate Agreement shall be resolved in favor of a
meaning that permits both parties to comply with the HIPAA Rules.
(e) Effective Date. This Business Associate Agreement shall be effective as of the effective date of the PBM
Agreement.
34
221479.v4
EXHIBIT D
FINANCIAL DISCLOSURE TO ESI PBM CLIENTS
This disclosure provides an overview of the principal revenue sources of Express Scripts, Inc. and Medco Health
Solutions, Inc. (individually and collectively referred to herein as "ESI"), as well as ESI's affiliates. In addition to
administrative and dispensing fees paid to ESI by our clients for pharmaceutical benefit management ("PBM") services, ESI
and its affiliates derive revenue from other sources, including arrangements with pharmaceutical manufacturers, wholesale
distributors,and retail pharmacies. Some of this revenue relates to utilization of prescription drugs by members of the clients
receiving PBM services. ESI may pass through certain manufacturer payments to its clients or may retain those payments
for itself, depending on the contract terms between ESI and the client.
Network Pharmacies—ESI contracts for its own account with retail pharmacies to dispense prescription drugs to client
members. Rates paid by ESI to these pharmacies may differ among networks (e.g., Medicare, Worker's Comp, open and
limited), and among pharmacies within a network, and by client arrangements. PBM agreements generally provide that a
client pays ESI an ingredient cost, plus dispensing fee, for drug claims. If the rate paid by a client exceeds the rate
contracted with a particular pharmacy, ESI will realize a positive margin on the applicable claim. The reverse also may be
true, resulting in negative margin for ESI. ESI also enters into pass-through arrangements where the client pays ESI the
actual ingredient cost and dispensing fee amount paid by ESI for the particular claim when the claim is adjudicated to the
pharmacy. In addition, when ESI receives payment from a client before payment to a pharmacy, ESI retains the benefit of
the use of the funds between these payments. ESI may maintain non-client specific aggregate guarantees with pharmacies
and may realize positive margin. ESI may charge pharmacies standard transaction fees to access ESI's pharmacy claims
systems and for other related administrative purposes.
Brand/Generic Classifications — Prescription drugs may be classified as either a "brand" or "generic;" however, the
reference to a drug by its chemical name does not necessarily mean that the product is recognized as a generic for
adjudication, pricing or copay purposes. For the purposes of pharmacy reimbursement, ESI distinguishes brands and
generics through a proprietary algorithm ("BGA") that uses certain published elements provided by First DataBank (FDB)
including price indicators, Generic Indicator, Generic Manufacturer Indicator, Generic Name Drug Indicator, Innovator, Drug
Class and ANDA. The BGA uses these data elements in a hierarchical process to categorize the products as brand or
generic. The BGA also has processes to resolve discrepancies and prevent"flipping" between brand and generic status due
to price fluctuations and marketplace availability changes. The elements listed above and sources are subject to change
based on the availability of the specific fields. Updated summaries of the BGA are available upon request. Brand or generic
classification for client reimbursement purposes is either based on the BGA or specific code indicators from Medi-Span or a
combination of the two as reflected in the client's specific contract terms. Application of an alternative methodology based
on specific client contract terms does not affect ESI's application of its BGA for ESI's other contracts.
Maximum Allowable Cost ("MAC")/Maximum Reimbursement Amount ("MRA") —As part of the administration of the
PBM services, ESI maintains a MAC List of drug products identified as requiring pricing management due to the number of
manufacturers, utilization and/or pricing volatility. The criteria for inclusion on the MAC List are based on whether the drug
has readily available generic product(s), is generally equivalent to a brand drug, is cleared of any negative clinical
implications, and has a cost basis that will allow for pricing below brand rates. ESI also maintains MRA price lists for drug
products on the MAC List based on current price reference data provided by MediSpan or other nationally recognized pricing
source, market pricing and availability information from generic manufacturers and on-line research of national wholesale
drug company files, and client arrangements. Similar to the BGA, the elements listed above and sources are subject to
change based on the availability of the specific fields. Updated summaries of the MAC methodology are available upon
request.
Manufacturer Programs Formulary Rebates, Associated Administrative Fees, and PBM Service Fees— ESI contracts
for its own account to obtain formulary rebates attributable to the utilization of certain brand drugs and supplies(and possibly
certain authorized generics marketed under a brand manufacturer's new drug application). Formulary rebate amounts
received vary based on client specific utilization, the volume of utilization as well as formulary position applicable to the drug
or supplies, and adherence to various formulary management controls, benefit design requirements, claims volume, and
other similar factors,and in certain instances also may vary based on the product's market-share. ESI often pays an amount
equal to all or a portion of the formulary rebates it receives to a client based on the client's PBM agreement terms. ESI or
its affiliates may maintain non-client specific aggregate guarantees and may realize positive margin. In addition, ESI
provides administrative services to contracted manufacturers, which include, for example, maintenance and operation of
systems and other infrastructure necessary for invoicing and processing rebates, pharmacy discount programs, access to
drug utilization data,as allowed by law,for purposes of verifying and evaluating applicable payments, and for other purposes
related to the manufacturer's products. ESI receives administrative fees from the participating manufacturers for these
services. These administrative fees are calculated based on the price of the drug or supplies along with the volume of
utilization and do not exceed the greater of(i)4.58% of the average wholesale price, or(ii)5.5%of the wholesale acquisition
cost of the products. In its capacity as a PBM company, ESI also may receive other compensation from manufacturers for
the performance of various programs or services, including, for example, formulary compliance initiatives, clinical services,
therapy management services, education services, inflation protection programs, medical benefit management services, cost
containment programs, discount programs, and the sale of non-patient identifiable claim information. This compensation is
not part of the formulary rebates or associated administrative fees, and ESI may realize positive margin between amounts
paid to clients and amounts received from pharmaceutical manufacturers. ESI retains the financial benefit of the use of any
funds held until payment is made to the client.
35
221479.v4
Copies of ESI's standard formularies may be reviewed at www.express-scripts.com/wps/portal/. In addition to
formulary considerations, other plan design elements are described in ESI's Plan Design Review Guide, which may be
reviewed at www.express-scripts.com/wps/portal/.
ESI Subsidiary Pharmacies — ESI has several licensed pharmacy subsidiaries, including our specialty pharmacies.
These entities may maintain product purchase discount arrangements and/or fee-for-service arrangements with
pharmaceutical manufacturers, wholesale distributors, and other health care providers. These subsidiary pharmacies
contract for these arrangements on their own account in support of their various pharmacy operations. Many of these
subsidiary arrangements relate to services provided outside of PBM arrangements, and may be entered into irrespective of
whether the particular drug is on one of ESI's national formularies. Discounts and fee-for-service payments received by
ESI's subsidiary pharmacies are not part of the PBM formulary rebates or associated administrative fees paid to ESI in
connection with ESI's PBM formulary rebate programs. However, certain purchase discounts received by ESI's subsidiary
pharmacies, whether directly or through ESI, may be considered for formulary purposes if the value of such purchase
discounts is used by ESI to supplement the discount on the ingredient cost of the drug to the client based on the client's
PBM agreement terms. From time to time, ESI and its affiliates also may pursue and maintain for its own account other
supply chain sourcing relationships not described below as beneficial to maximize ESI's drug purchasing capabilities and
efficiencies, and ESI or affiliates may realize an overall positive margin with regard to these initiatives.
The following provides additional information regarding examples of ESI subsidiary discount arrangements and fee-
for-service arrangements with pharmaceutical manufacturers, and wholesale distributors:
ESI Subsidiary Pharmacy Discount Arrangements — ESI subsidiary pharmacies purchase prescription drug
inventories, either from manufacturers or wholesalers, for dispensing to patients. Often, purchase discounts off the
acquisition cost of these products are made available by manufacturers and wholesalers in the form of either up-front
discounts or retrospective discounts. These purchase discounts, obtained through separate purchase contracts, are
not formulary rebates paid in connection with our PBM formulary rebate programs. Drug purchase discounts are
based on a pharmacy's inventory needs and, at times, the performance of related patient care services and other
performance requirements. When a subsidiary pharmacy dispenses a product from its inventory, the purchase price
paid for the dispensed product, including applicable dispensing fees, may be greater or less than that pharmacy's
acquisition cost for the product net of purchase discounts. In general, our pharmacies realize an overall positive
margin between the net acquisition cost and the amounts paid for the dispensed drugs.
ESI Subsidiary Fee-For-Service Arrangements — One or more of ESI's subsidiaries, including, but not limited to, its
subsidiary pharmacies also may receive fee-for-service payments from manufacturers, wholesalers, or other health
care providers in conjunction with various programs or services, including, for example, patient assistance programs
for indigent patients,dispensing prescription medications to patients enrolled in clinical trials, various therapy
adherence and fertility programs, administering FDA compliance requirements related to the drug, 340B contract
pharmacy services, product reimbursement support services, and various other clinical or pharmacy programs or
services. As a condition to having access to certain products, and sometimes related to certain therapy adherence
criteria or FDA requirements, a pharmaceutical manufacturer may require a pharmacy to report selected information
to the manufacturer regarding the pharmacy's service levels and other dispensing-related data with respect to
patients who receive that manufacturer's product. A portion of the discounts or other fee-for-service payments made
available to our pharmacies may represent compensation for such reporting.
Other Manufacturer Arrangements—ESI also maintains other lines of business that may involve discount and service
fee relationships with pharmaceutical manufacturers and wholesale distributors. Examples of these businesses
include a wholesale distribution business, group purchasing organizations (and related group purchasing organization
fees), a medical benefit management company, and United BioSource Corporation ("UBC"). Compensation derived
through these business arrangements is not considered for PBM formulary placement, and is in addition to other
amounts described herein. Of particular note, UBC partners with life sciences and pharmaceutical companies to
develop, commercialize, and support safe, effective use and access to pharmaceutical products. UBC maintains a
team of research scientists, biomedical experts, research operations professionals, technologists and clinicians who
work with clients to conduct and support clinical trials, create, and validate and administer pre and post product safety
and risk management programs. UBC also works on behalf of pharmaceutical manufacturers to provide product and
disease state education programs, reimbursement assistance, and other support services to the public at large.
These service fees are not part of the formulary rebates or associated administrative fees.
Third Party Data Sales—Consistent with any client contract limitations, ESI or its affiliates may sell HIPAA compliant
information maintained in their capacity as a PBM, pharmacy, or otherwise to data aggregators, manufacturers, or
other third parties on a fee-for-service basis or as a condition of discount eligibility. All such activities are conducted
in compliance with applicable patient and pharmacy privacy laws and client contract restrictions.
October 1, 2015
THIS EXHIBIT REPRESENTS ESI'S FINANCIAL POLICIES. ESI MAY PERIODICALLY UPDATE THIS EXHIBIT AND
THE FINANCIAL DISCLOSURES CONTAINED HEREIN TO REFLECT CHANGES IN ITS BUSINESS PROCESSES; THE
CURRENT FINANCIAL DISCLOSURE IS AVAILABLE UPON REQUEST AND ACCESSIBLE ON EXPRESS-
SCRIPTS.COM AT WWW. EXPRESS-SCRIPTS.COM/WPS/PORTAL/.
36
221479.v4
EXHIBIT E
PERFORMANCE STANDARDS
In the event that any failure by ESI to meet any performance standard is due to a "force majeure" as
defined in the Agreement, failure of Sponsor to perform its obligations under the Agreement, or actions or
inactions of Sponsor that adversely impact ESI's ability to maintain the subject standard (e.g., faulty eligibility,
changes in benefit design not adequately communicated to Members and benefit designs that substantially
change the Members' rights under the Plan), ESI will be excused from compliance with such performance
standards until such circumstances have been resolved and any existing backlogs or other related effects have
been eliminated.
Within ninety (90) days after the end of each year, ESI shall report to Sponsor ESI's performance under
each performance standard. Notwithstanding the foregoing, for purposes of determining whether ESI has met
or failed to meet each performance standard, performance standards will be measured and reconciled on an
annual basis and amounts due resulting from an ESI failure to meet any performance standard(s), if any, shall
be calculated and paid to Sponsor within thirty (30) days following Sponsors receipt of reconciliation report.
No performance penalties, if any, will be paid until this Agreement is executed by Sponsor. In no event
will the sum of the payments to Sponsor, as a result of ESI's failure to meet the performance standards exceed
$10.00 per Member up to a maximum of$53,250 per year for the annual performance standards.
The following performance standards are based on 5,325 Members as of the Effective Date and
throughout the Term. Any material change below such number may result in a renegotiation of the standards
and penalties set forth below.
Performance standards for ESI's Mail Service Pharmacy assume a minimum of 1,000 Mail Service
Pharmacy prescriptions submitted annually.
Service Feature Standard Penalty
Client Services Administration
Satisfaction Survey One random sample member survey will be completed ESI will put$3,400 as a total
annually on a book-of-business basis. ESI guarantees a amount of penalty at risk.
patient satisfaction rate of 90%or greater. This standard
will be measured and reported annually.
Contact Center
Average Speed of ESI guarantees that calls will be answered in an average of ESI will pay Sponsor$1,700
Answer 30 seconds or less.This standard is predicated on the for each full second above
installation of a toll-free number unique to the Sponsor. the standard 30 seconds on
an annual basis.The
maximum annual penalty will
be$3,400.The calculation
will be based on the average
speed of answer.
Blockage Rate ESI will guarantee a blockage rate of 1%or less. Blockage ESI will pay Sponsor$1,700
(Busy Signal) is defined as a caller receiving a busy signal. for each full percentage point
This standard is predicated on the installation of a toll-free above the standard 1%on an
number unique to Sponsor. annual basis.The maximum
annual penalty will be$3,400.
The calculation will be based
on the blockage percentage.
Percent of Calls The Telephone Abandonment Rate of the Member Service ESI will pay Sponsor$1,700
Abandoned Telephone Line will be 3%or less of all incoming calls for each full percentage point
received during each Contract Year. above the standard 3%on an
annual basis.The maximum
annual penalty will be$3,400.
The calculation will be based
on the average percentage of
calls abandoned.
37
221479.v4
Service Feature Standard Penalty
Customer Service— ESI guarantees that 94%or greater of patient calls will be ESI will pay Sponsor$1,700
First Call Resolution resolved on the first call. for each full percentage point
below 94%.The maximum
annual penalty will be$3,400.
Home Delivery Pharmacy
Dispensing Accuracy The Dispensing Accuracy Rate for each Contract Year will ESI will pay Sponsor$1,700
be 99.996%or greater. Standard is measure at book of for each full percentage point
business. below the standard of
99.996%on an annual basis.
The maximum annual penalty
will be$3,400.The
calculation will be based on
the average prescription
accuracy.
Turnaround Time for ESI guarantees to dispense prescriptions not subject to ESI will pay Sponsor$1,700
Routine(Clean) intervention within an average of two(2) business days. for each full day above the
Prescriptions standard two(2) business
days on an annual basis.The
maximum annual penalty will
be$3,400.
Turnaround Time for ESI guarantees to dispense prescriptions subject to ESI will pay Sponsor$1,700
Prescriptions Subject to intervention within an average of four(4) business days. for each full day above the
Intervention standard four(4)business
days on an annual basis.The
maximum annual penalty will
be$3,400.
Data Systems
Data Systems Availability ESI guarantees an annual average 99%system availability ESI will pay Sponsor$1,700
and Adjudication of the point-of-sale adjudication system on a book-of- for each full percentage point
business basis. which the yearly average of
This standard excludes systems downtime attributed to the online computer systems
regularly scheduled systems maintenance or systems availability is below 99%.The
downtime attributed to telecommunications failure or other maximum annual penalty for
circumstances outside the control of ESI. availability and adjudication
will be$3,400.
Claims Adjudication Accuracy
Claims Adjudication The Claims Adjudication Accuracy Rate for each Contract ESI will put$3,400 as a total
Accuracy Year will be 99%or greater."Claims Adjudication Accuracy amount of penalty at risk.
Rate"means(i)the total number of claims adjudicated and
paid accurately by ESI in a Contract Year, divided by(ii)the
total number of claims adjudicated and paid during the
measurement period. Measured on a book of business
basis.
Reporting
Timely Production of ESI guarantees access to the online Trend Central reporting ESI will put$3,400 as a total
Management Reports- suite will be available within an annual average of fifteen amount of penalty at risk.
Monthly (15) business days after the billing cycle that contains the
last day of the month.
Timely Production of ESI guarantees access to the online Trend Central reporting ESI will put$3,400 as a total
Management Reports- suite data will be available within an annual average of thirty amount of penalty at risk.
Quarterly (30) business days after the billing cycle that contains the
last day of the quarter.
Replacement ID Card Production
Timely Production of ESI guarantees that standard replacement ID cards will be ESI will put$3,400 as a total
Replacement ID Cards produced within an annual average of five(5) business days amount of penalty at risk.
of the receipt and update of machine-readable eligibility
information.
Eligibility
38
221479.v4
Service Feature Standard Penalty
Eligibility—Timeliness Accurate and complete eligibility files electronically ESI will put$3,400 as a total
of Installations transmitted by 10:00 A.M. EST, via secured processes amount of penalty at risk.
acceptable to ESI,will be updated within two(2) business
days of receipt.
Account Management
Account Management Sponsor may assess a penalty per contract year if, after the ESI will put$3,400 as a total
Satisfaction first contract year and each successive contract year,those amount of penalty at risk.
Sponsor employees who are members of the Sponsor
benefits staff do not rate the ESI account team's
performance for each contract year on average of 5 or
better on a scale of 1 to 7(7 being the best) based on a
range of performance criteria agreed to between Sponsor
and ESI at the beginning of such contract Year.Additional
Sponsor staff members may be included in the survey at the
request of ESI.
Core Adjudication Platform Change
Core Adjudication ESI will agree that during the term of the Agreement, should ESI will put$3,400 as a total
Platform Change ESI propose to make a core adjudication platform change amount of penalty at risk.
that is likely to have a material impact on Sponsor, such as
the recent conversion to ESI's Foundation 14 claims
adjudication platform, ESI will ensure adequate notice to
the Sponsor and their membership regarding any potential
changes or impact.
39
221479.v4
CERTIFICATE OF INTERESTED PARTIES FORM 1295
1 ol 1
Complete Nos.1-4 and 6 if there are interested parties. OFFICE USE ONLY
Complete Nos.1,2.3,5,and 6 if there are no interested parties. CERTIFICATION OF FILING
1 Name of business entity filing form,and the city,state and country of the business entity's place Certificate Number:
of business.
2016-95581
Express Scripts,Inc.
St.Louis. MO United States Date Filed:
2 Name of governmental entity or state agency that is a party to the contract for which the form is 08/05/2016
being filed.
City of Corpus Christi Date Acknowledged:—r,
3 Provide the identification number used by the governmental entity or state agency to track or identify-the=contract.and provide a
description of the services,goods,or other property to be provided under the contract.
15-0599
Pharmacy Benefit Management Service
Nature of interest
4
Name of Interested Party City,State,Country(place of business) (check applicable)
Controlling Intermediary
Akins,Marty St. Louis,MO United States X
Express Scripts Holding Company St. Louis,MO United States X
5 Check only if there is NO Interested Party. ❑
6 AFFIDAVIT I swear.or affirm.under penalty of penury,that the above disclosure is true and correct.
PATRiCIA E.k.;.,
Notary Pubilu-Itds',sry 5r;ai ir /
CofttTiss ?.lls Cit)t
My C000rr•f .. Jmite 21 2018 Signature of authorized a,ent of contracting business entity
AFFIX NOTARY STAMP/SEAL ABOVE /
Swor (and subscribed before me,by the said sl this the day of_.
20 If ,to certify which,witness my hand and seal of office.
Si attire of officer administering oath Printed name of officer administering oath Title of officer administering oath
Forms provided by Texas Ethics Commission www.ethics.state.tx.us Version V1.0.277